基石药业
CSTONE
PHARMACEUTICALS

CStone Pharmaceuticals
基石藥業

(Incorporated in the Cayman Islands with limited liability)
(於開曼群島註冊成立的有限公司)

Stock Code 股份代號 : **2616**

2025 Interim Report
中 期 報 告

Contents

Corporate Information

BOARD OF DIRECTORS

Executive Director

Dr. Jianxin Yang *(Chief Executive Officer)*

Non-executive Directors

Dr. Wei Li *(Chairman)*
Mr. Kenneth Walton Hitchner III
Mr. Xianghong Lin *(retired on June 25, 2025)*
Mr. Edward Hu

Independent Non-executive Directors

Dr. Paul Herbert Chew *(retired on June 25, 2025)*
Mr. Ting Yuk Anthony Wu
Mr. Hongbin Sun *(resigned on June 25, 2025)*
Ms. Yip Betty Ho
Mr. Kenneth Howard Jarrett *(appointed on September 23, 2025)*

AUDIT COMMITTEE

Mr. Hongbin Sun *(Chairman) (resigned on June 25, 2025)*
Ms. Yip Betty Ho *(Chairperson) (appointed on June 25, 2025)*
Dr. Paul Herbert Chew *(retired on June 25, 2025)*
Mr. Ting Yuk Anthony Wu
Mr. Kenneth Howard Jarrett *(appointed on September 23, 2025)*

COMPENSATION COMMITTEE

Mr. Ting Yuk Anthony Wu *(Chairman)*
Dr. Wei Li
Dr. Paul Herbert Chew *(retired on June 25, 2025)*
Ms. Yip Betty Ho *(appointed on June 25, 2025)*

NOMINATION COMMITTEE

Dr. Wei Li *(Chairman)*
Dr. Paul Herbert Chew *(retired on June 25, 2025)*
Mr. Ting Yuk Anthony Wu
Mr. Hongbin Sun *(resigned on June 25, 2025)*
Ms. Yip Betty Ho *(appointed on June 25, 2025)*

STRATEGY COMMITTEE

Dr. Jianxin Yang *(Chairman)*
Mr. Edward Hu
Dr. Paul Herbert Chew *(retired on June 25, 2025)*
Ms. Yip Betty Ho *(appointed on June 25, 2025)*
Mr. Kenneth Howard Jarrett *(appointed on September 23, 2025)*

INVESTMENT COMMITTEE

Mr. Edward Hu *(Chairman)*
Mr. Kenneth Walton Hitchner III
Mr. Hongbin Sun *(resigned on June 25, 2025)*
Ms. Yip Betty Ho *(appointed on June 25, 2025)*

AUTHORIZED REPRESENTATIVES

Dr. Jianxin Yang
Ms. Mei Yee Yung

JOINT COMPANY SECRETARIES

Ms. Weicong Ni
Ms. Mei Yee Yung

COMPANY WEBSITE

www.cstonepharma.com

REGISTERED OFFICE

The offices of Vistra (Cayman) Limited
P.O. Box 31119, Grand Pavilion
Hibiscus Way
802 West Bay Road
Grand Cayman KY1-1205
Cayman Islands

HEAD OFFICE AND PRINCIPAL PLACE OF BUSINESS IN CHINA

C1 Building, North Block
218 Xinghu Str.
Suzhou Industrial Park
China

PRINCIPAL PLACE OF BUSINESS IN HONG KONG

40th Floor, Dah Sing Financial Centre
No. 248 Queen's Road East
Wanchai
Hong Kong

PRINCIPAL SHARE REGISTRAR

Walkers Corporate Limited
Cayman Corporate Centre
27 Hospital Road
George Town
Grand Cayman KY1-9008
Cayman Islands

HONG KONG SHARE REGISTRAR

Computershare Hong Kong Investor Services Limited
Shops 1712-1716
17th Floor, Hopewell Centre
183 Queen's Road East
Wanchai
Hong Kong

HONG KONG LEGAL ADVISER

Fangda Partners
26/F, One Exchange Square
8 Connaught Place
Central
Hong Kong

COMPLIANCE ADVISER

Rainbow Capital (HK) Limited
Office No. 710, 7/F, Wing On House
71 Des Voeux Road Central
Hong Kong

STOCK CODE

2616

AUDITOR

Deloitte Touche Tohmatsu
Registered Public Interest Entity Auditors
35/F, One Pacific Place
88 Queensway
Admiralty
Hong Kong

Financial Highlights

International Financial Reporting Standards ("IFRS") Measures:

- **Revenue** was RMB49.4 million for the six months ended June 30, 2025, representing a decrease of RMB204.8 million or 80.5% compared to RMB254.2 million for the six months ended June 30, 2024. The revenue is composed of RMB20.2 million from sales of pharmaceutical products (avapritinib, pralsetinib), RMB17.9 million from license fee income and RMB11.3 million from royalty income of sugemalimab. (1) Revenue from sales of pralsetinib decreased substantially period-on-period, which is primarily due to price adjustments of pralsetinib in preparation for the National Reimbursement Drug List ("**NRDL**") negotiation and related one-off channel compensation. If included in NRDL, benefit from sales ramp up of pralsetinib in 2026 and beyond is expected to overweigh short-term negative impact on revenue. (2) License fee income also decreased substantially period-on-period, primarily due to the fact that we received a strong contribution from a one-time milestone payment for sugemalimab gastric cancer approval in China in the first half of 2024. No material out-licensing arrangement was entered into during the first half of 2025, however, the major out-licensing agreement with Istituto Gentili ("**Gentili**") in July 2025 is expected to contribute to license fee income for the second half of 2025.

- **Cost of revenue** was RMB142.2 million for the six months ended June 30, 2025, representing an increase of RMB60.1 million from RMB82.1 million for the six months ended June 30, 2024, primarily due to inventory write-downs charged to cost of revenue and cost associated with an early billing of pralsetinib supply under the Patient Assistance Program covering the period through the first half of 2026 to mitigate customs clearance risks amid trade uncertainties.

- **Research and development expenses** were RMB105.2 million for the six months ended June 30, 2025, representing an increase of RMB39.0 million from RMB66.2 million for the six months ended June 30, 2024, primarily due to increased costs for clinical trials.

- **Administrative expenses** were RMB43.5 million for the six months ended June 30, 2025, representing a decrease of RMB3.2 million from RMB46.7 million for the six months ended June 30, 2024, primarily due to a decrease in depreciation and amortization.

- **Selling and marketing expenses** were RMB35.7 million for the six months ended June 30, 2025, representing a decrease of RMB27.1 million from RMB62.8 million for the six months ended June 30, 2024, primarily due to a decrease in channel service fee and others.

- **Loss for the period** was RMB270.2 million for the six months ended June 30, 2025, representing an increase in loss of RMB285.9 million, from a profit of RMB15.7 million for the six months ended June 30, 2024, primarily due to a shift from gross profit to gross loss.

- **Cash and cash equivalents and time deposits** were RMB652.8 million as of June 30, 2025.

Non-International Financial Reporting Standards ("Non-IFRS") Measures:

- **Research and development expenses** excluding the share-based payment expenses were RMB102.1 million for the six months ended June 30, 2025, representing an increase of RMB31.1 million from RMB71.0 million for the six months ended June 30, 2024, primarily due to increased costs for clinical trials.

- **Administrative and selling and marketing expenses** excluding the share-based payment expenses were RMB77.2 million for the six months ended June 30, 2025, representing a decrease of RMB32.4 million from RMB109.6 million for the six months ended June 30, 2024, primarily due to a decrease in channel service fee and others.

- **Loss for the period** excluding the share-based payment expenses was RMB265.1 million for the six months ended June 30, 2025, representing an increase in loss of RMB275.9 million, from a profit of RMB10.8 million for the six months ended June 30, 2024, primarily due to a shift from gross profit to gross loss.

Business Highlights

For the six months ended June 30, 2025 and up to the date of this interim report, we accelerated our global expansion strategy, advanced our differentiated pipeline, and strengthened our commercial footprint through strategic partnerships. Key achievements during this period include regulatory approvals, clinical advancements, and strategic collaborations, collectively reinforcing our position in developing innovative therapeutics.

Commercial Products

- ***CEJEMLY® (sugemalimab), anti-PD-L1 antibody***

  – *Global expansion and regulatory approvals*

  Following sugemalimab's approvals for stage IV non-small cell lung cancer ("**NSCLC**") in the European Union ("**EU**") and United Kingdom ("**U.K.**") last year, we submitted a new indication application in March 2025 to the European Medicines Agency ("**EMA**") for the treatment of patients with unresectable stage III NSCLC who have not progressed following concurrent or sequential platinum-based chemoradiotherapy ("**CRT**"). If approved, sugemalimab would address a critical unmet need in stage III NSCLC, where only one anti-PD-(L)1 antibody is currently approved in Europe.

  – *Global commercialization driven by strategic alliances*

  In January 2025, we entered into a partnership with SteinCares to commercialize sugemalimab across ten countries in Latin America ("**LATAM**"). This was followed by a partnership with Gentili in July 2025 to commercialize sugemalimab in 23 countries in Western Europe and the United Kingdom. To date, four partnerships have been executed extending sugemalimab's international footprint to over 60 countries around the world. Additional partnerships in Southeast Asia, Canada, and other markets are expected in the near future.

  – *Robust data reinforcing clinical impact*

  - **Publications in top-tier journals:** In February 2025, the results of the final progression-free survival ("**PFS**") and overall survival ("**OS**") for the GEMSTONE-303 study (for first-line gastric cancer/gastroesophageal junction cancer GC/GEJC) were published in JAMA (Journal of the American Medical Association). In June 2025, long-term survival data from the GEMSTONE-302 study (for first-line stage IV NSCLC) were published in the Lancet Oncology, marking the trial's third publication in top-tier journals.

  - **Global guideline adoption:** Sugemalimab has been incorporated into the Non-Oncogene-Addicted Metastatic NSCLC Living Guideline of the European Society for Medical Oncology ("**ESMO**") in February 2025 and is recommended as a Level I, A first-line combination therapy for both squamous and non-squamous NSCLC.

- ***GAVRETO® (pralsetinib), rearranged during transfection (RET) inhibitor***

  – *Localized production approved*

  In July 2025, the China National Medical Products Administration ("**China NMPA**") approved the manufacturing localization application for GAVRETO® (pralsetinib, 100mg). Commencing in 2026, the Chinese market supply will transition gradually from imports to end to end domestic production, from active pharmaceutical ingredient to finished drug product, significantly enhancing cost efficiency and supply chain resilience.

  – *NRDL negotiation*

  In August 2025, pralsetinib has passed the formal review for the 2025 NRDL negotiation.

- ***AYVAKIT® (avapritinib), KIT/PDGFRA inhibitor***

  – *Domestic supply launch*

  Following the China NMPA approval for localization production of AYVAKIT® tablets (300 mg and 100 mg) in 2024, domestic supply of AYVAKIT® commenced in February 2025. This shift is projected to drive gross margin expansion.

Clinical Stage Core Assets

- ***CS5001, ROR1 Antibody-drug Conjugates (ADC)***

  – *Global Phase Ib trial progress*

  The global multicenter clinical trial of CS5001 is actively enrolling patients across Australia, China and the United States of America ("**U.S.**"). Recruitment efforts are prioritizing combination therapy cohorts, including CS5001 in combination with R-CHOP (Rituximab + Cyclophosphamide + Hydroxydaunorubicin + Vincristine + Prednisone) for the first-line diffuse large B-cell lymphoma ("**DLBCL**"), and CS5001 in combination with standard of cares ("**SOC**") for front-line DLBCL. No dose-limiting toxicity ("**DLT**") was observed to date. Additionally, enrollment is ongoing for monotherapy cohorts targeting aggressive and indolent advanced lymphomas with potential to be expanded into a Phase II single-arm registrational study. CS5001 is also being studied both as a monotherapy and in combination with sugemalimab for advanced solid tumors, underscoring its clinical potential across oncological indications.

- ***CS2009, PD-1/VEGF/CTLA-4 trispecific antibody***

  – *Global multicenter Phase I/II trial progress*

  The global multicenter Phase I/II study is rapidly enrolling patients in Australia and China, with planned expansion to the U.S. for Phase II enrollment. Phase I data including safety, pharmacokinetic ("**PK**"), pharmacodynamic ("**PD**"), and antitumor activity will be presented at ESMO Congress in October 2025. In September 2025, the first patient has been enrolled in Australia in the Phase II clinical trial.

– *First-in-class ("**FIC**")/best-in-class ("**BIC**") potential and next-generation I/O backbone*

In the Phase I dose-escalation study (6 cohorts, 1-45mg/kg, escalation and backfilling), CS2009 showed:

- **Favorable Safety:**

  No dose-limiting toxicities (DLT) observed across all evaluated doses; well-tolerated in dozens of patients.

- **PK/PD Characteristics as Expected:**

  Every-three-week (Q3W) dosing supported by linear pharmacokinetic with no accumulation;

  Robust T-cell activation/proliferation via PD-1/CTLA-4 blockade and potent and sustained VEGFA neutralization.

- **Broad and Deepening Antitumor Activity:**

  Notable anti-tumor activity was observed across all doses, and the activity continued to enhance with prolonged follow-up;

  Activity demonstrated in multiple tumors, including cold tumors and PD-(L)1-refractory patients;

  Most patients remain on continued treatment.

- ***Nofazinlimab, anti-PD-1 antibody***

  – *Final analysis of CS1003-305*

  In July 2025, the final analysis of the global multicenter Phase III CS1003-305 study demonstrated a clinical compelling trend in OS for the nofazinlimab-lenvatinib combination compared to placebo-lenvatinib, indicating meaningful patient benefit despite not reaching statistical significance. In addition, clinically meaningful improvements in PFS and objective response rate ("**ORR**") were achieved and no new safety signals were observed. We will engage with regulatory authorities to explore the registration pathway for this combination therapy.

Preclinical/IND (Investigational New Drug)-enabling Stage Programs and Proprietary ADC Platform

CStone's preclinical pipeline compromises over nine promising candidates across multispecific antibodies, ADC etc. These programs focus on FIC/BIC profiles covering various therapeutic fields such as oncology, autoimmune and inflammatory diseases. We are dedicated to delivering clinical value through the development of these Pipeline 2.0 candidates, which will undergo international, multi-center clinical trials to maximize their global potential.

Our innovative in-house ADC technology platform features optimized proprietary linkers improving tumor-selective payload release. This platform supports multiple ADC products in Pipeline 2.0, including CS5007 (dual targeting epidermal growth factor receptor EGFR and human epidermal growth factor receptor 3 HER3 bispecific ADC), CS5005 (somatostatin receptor 2 SSTR2 ADC), CS5008 (delta-like ligand 3 DLL3 and SSTR2 bispecific ADC), CS5006 (integrin β4 ITGB4 ADC), CS5009 (B7H3/PD-L1 bispecific ADC), etc.

In May 2025, we presented preclinical data for CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody), CS2011 (EGFR/HER3 bispecific antibody), CS5007 (EGFR/HER3 bispecific ADC), CS5006 (ITGB4 ADC) and CS5005 (SSTR2 ADC) at the 2025 annual meeting of the American Association for Cancer Research ("**AACR**").

In July 2025, we disclosed the targets of two autoimmune/inflammatory candidates, CS2013 (B-cell-Activating Factor BAFF/A Proliferation-Inducing Ligand APRIL bispecific antibody) and CS2015 (OX40 Ligand OX40L/Thymic Stromal Lymphopoietin TSLP bispecific antibody). Both have FIC/BIC potential, and IND-enabling studies with respect to both are expected to be initiated in the second half of 2025. These candidates reflect our strategic expansion into non-oncology therapeutic pipelines.

FUTURE AND OUTLOOK

Our mission is to deliver transformative therapies through scientific excellence and technological innovation, making high-quality treatments accessible worldwide to benefit patients and their families.

We reaffirm our commitment to advancing a robust and differentiated pipeline by prioritizing internal discovery capabilities and sustained R&D investments, while executing strategic partnerships to unlock the global value of our in-market products. Critical catalysts for the second half of 2025 include:

- **Clinical milestones:**
  - Progress CS5001 (ROR1 ADC) and CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) towards pivotal trials and in parallel pursue global partnerships to expedite development.
  - Advance early-stage candidates into clinical stages.
- **Commercial excellence:**
  - Maximize the value of AYVAKIT® and GAVRETO® through strategic collaborations and potential transactions.
  - Continue to accelerate ex-China commercialization of sugemalimab via regional partnerships.
- **Innovation and technology:**
  - Strengthen proprietary platforms (e.g., ADC technology) to sustain pipeline growth.
  - Present key clinical data at major conferences (e.g., ESMO, American Society of Hematology ("**ASH**")).

CAUTIONARY STATEMENT REQUIRED BY RULE 18A.08(3) OF THE LISTING RULES: WE MAY NOT BE ABLE TO ULTIMATELY DEVELOP OR MARKET ANY OF OUR PIPELINE PRODUCTS SUCCESSFULLY.

Management Discussion and Analysis

OUR VISION

To be a pioneer in enhancing global patient health through innovation.

OVERVIEW

CStone (HKEX: 2616), established in late 2015, is an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, and other key disease areas. Dedicated to addressing patients' unmet medical needs in China and globally, the Company has made significant strides since its inception. To date, the Company has successfully launched 4 innovative drugs and secured approvals for 16 New Drug Application ("**NDAs**") covering 9 indications. The Company's pipeline is balanced by 16 promising candidates, featuring potentially FIC or BIC ADCs, multispecific antibodies, immunotherapies and precision medicines. CStone also prides itself on a management team with comprehensive experiences and capabilities that span the entire drug development spectrum, from preclinical and translational research to clinical development, drug manufacturing, business development, and commercialization. For details of any of the foregoing, please refer to the rest of this interim report and, where applicable, the Prospectus and prior announcements published on the websites of The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") and the Company.

Product Pipeline

The following pipeline chart demonstrates the milestone and development status of our selected assets as of the date of this interim report:

Well-balanced portfolio of 16 innovative assets
– Commercial/Late-stage Programs

Drug candidate	Indication	POC	Pivotal	NDA	Marketed	Approval						Partners	Partnering regions
						CN	TW	HK	US	EU	UK		
Pralsetinib (RET)	2L NSCLC					✓	✓	✓	✓			sanofi, rigel	◀ Mainland China
	1L NSCLC					✓	✓	✓	✓				
	1L MTC / TC					✓	✓ (TC)		✓ (TC)				
	Multiple tumors												
Avapritinib (KIT/PDGFRA)	PDGFRA exon 18 GIST					✓	✓	✓	✓			sanofi	◀ Mainland China
	SM[1]								✓				
Sugemalimab (PD-L1)	1L Stage IV NSCLC					✓						Pfizer	◀ Mainland China
	1L Stage IV NSCLC									✓	✓		
	Stage III NSCLC					✓						EWO pharma	◀ Switzerland and Central Eastern Europe
	1L GC/GEJ					✓						PHARMALINK	◀ Middle East and Africa
	1L ESCC					✓							
	R/R ENKTL					✓						STEINCARES	◀ Latin America
	R/R ENKTL											GENTILI	◀ West Europe and the UK
CS1003 (PD-1)	1L HCC											三生制药	◀ Mainland China
CS1002 (CTLA-4)	Solid tumors												◀ Greater China

Note: Assets status denotes progress in the region(s) noted in the column titled "Rights"; CN = Mainland China, TW = Taiwan, China, HK = Hong Kong SAR, China, US = United States, POC = Proof of Concept, NSCLC = Non-small Cell Lung Cancer, MTC = Medullary Thyroid Cancer, TC = Thyroid Cancer, GIST = Gastrointestinal Stromal Tumor, SM = Systemic Mastocytosis, GC/GEJ = gastric adenocarcinoma/gastroesophageal junction adenocarcinoma, ESCC = Esophageal Squamous Cell Carcinoma, R/R = Relapsed or Refractory, NKTL = Natural KILLER/T Cell Lymphoma, HCC = Hepatocellular Carcinoma; RoW, Rest of World
1. POC was conducted in the U.S. and no clinical trials have been conducted in China;

Greater China | Global Rights | Expedited registration

Well-balanced portfolio of 16 innovative assets
– Pipeline 2.0



Note: Assets status denotes progress in the region(s) noted in the column titled "Rights"; FIH = First in Human, POC = Proof of Concept,
1. CStone obtains the exclusive global right from LigaChem Biosciences, Inc. (LCB) to lead development and commercialization of LCB71/CS5001 outside the Republic of Korea

BUSINESS REVIEW

Commercial Products

Our partnerships with pharmaceutical and biotech companies are cornerstones of our near-term commercial plans as well as our global aspirations. In order to further improve the commercialization efficiency, we have established commercial collaborations with multiple companies to leverage their strengths while enabling us to strategically focus on research and development going forward.

Details on our commercial portfolio are set out below:

- ***CEJEMLY® (sugemalimab, anti-PD-L1 antibody) approved in China, E.U. and the U.K., expanding global presence and commercial value***

  – Sugemalimab, developed by CStone using the OmniRat® transgenic animal platform, is a fully human, full-length anti-PD-L1 immunoglobulin G4 (IgG4) monoclonal antibody, which may reduce the risk of immunogenicity and toxicity for patients.

  – Approved indications in different territories.

  The China NMPA has approved sugemalimab for five indications:

  - **Stage IV NSCLC:** In combination with chemotherapy as first-line treatment of patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations and metastatic squamous NSCLC;

  - **Stage III NSCLC:** For patients with unresectable Stage III NSCLC whose disease has not progressed following concurrent or sequential platinum-based chemoradiotherapy;

- **NK/T-cell lymphoma:** For patients with relapsed or refractory extranodal NK/T-cell lymphoma;

- **ESCC:** In combination with fluorouracil and platinum-based chemotherapy as first-line treatment of patients with unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma ("**ESCC**"); and

- **G/GEJ:** In combination with fluoropyrimidine- and platinum-containing chemotherapy as first-line treatment for unresectable locally advanced or metastatic gastric or gastroesophageal junction ("**G/GEJ**") adenocarcinoma with PD-L1 combined positive score ("**CPS**") ≥5.

The European Commission ("**EC**") and the Medicines and Healthcare products Regulatory Agency ("**MHRA**") in the U.K. have approved sugemalimab (brand name: CEJEMLY®) in combination with platinum-based chemotherapy for the first-line treatment of patients with metastatic NSCLC with no sensitizing EGFR mutations, or ALK, receptor tyrosine kinase-like orphan receptor 1 ("**ROS1**") or RET genomic tumor aberrations. We have completed the submission to EMA for the new indication application of Stage III NSCLC. If approved, sugemalimab's dual utility in Stages III and IV NSCLC could solidify its role as a cornerstone immunotherapy in lung cancer. We continue to engage with health authorities in Europe and other regions for other indications of sugemalimab.

– Commercial collaborations

  Building on our 2024 partnerships with Ewopharma and Pharmalink, we entered into a strategic agreement with SteinCares in January 2025 to commercialize sugemalimab across 10 LATAM countries. In July 2025, we signed an exclusive license agreement with Gentili covering 23 European countries, expanding sugemalimab's global reach to over 60 countries and regions. Under the terms of the agreement with Gentili, CStone is eligible to receive up to US$192.5 million in total consideration, including an upfront payment and milestone-based payments. CStone will supply the product and recognize approximately 50% of net sales from the licensed territories as revenue, while Gentili will lead all local regulatory and commercial activities in the covered regions.

– Guideline and academic recognition

  - **ESMO Guideline recommendation:** In February 2025, CEJEMLY® (sugemalimab) has been included in the ESMO NSCLC Living Guideline. Sugemalimab is recommended as a Level I, A first-line combination therapy for both non-oncogene-addicted metastatic squamous and non-squamous NSCLC, with substantial clinical benefits. This is another significant milestone in sugemalimab's global journey and provides critical support for our efforts to expand global market access and benefit patients.

  - **Publications and presentations:** In February 2025, the results of the PFS and OS final analysis in the registrational GEMSTONE-303 study (first-line G/GEJ with CPS≥5) were published in a top-tier medical journal – *Journal of the American Medical Association*. In June 2025, long-term survival data of the GEMSTONE-302 trial on sugemalimab was published in the Lancet Oncology. It is the trial's third publication in prestigious journals.

- ***GAVRETO® (pralsetinib, RET inhibitor) commercial partnership with Allist execution on track and manufacturing localization approved by China NMPA***

  – GAVRETO® (pralsetinib), a FIC RET inhibitor in China, has been approved by the China NMPA for the first-line treatment of adults with locally advanced or metastatic RET fusion-positive NSCLC, the treatment of adults with locally advanced or metastatic RET fusion-positive NSCLC previously treated with platinum-based chemotherapy; and the treatment of patients with advanced or metastatic RET-mutant medullary thyroid cancer ("**MTC**") and RET fusion-positive thyroid cancer ("**TC**"). In addition, this medicine has been approved by the Department of Health of the Government of Hong Kong ("**HK DoH**") for the treatment of patients with RET fusion-positive locally advanced or metastatic NSCLC and it has been approved by the Taiwan Food and Drug Administration ("**TFDA**") for the treatment of adult patients with locally advanced or metastatic RET fusion-positive NSCLC and advanced or metastatic RET fusion-positive TC.

  – In 2025, we continue to integrate GAVRETO® (pralsetinib) into Allist's highly synergistic lung cancer franchise, enabling GAVRETO® (pralsetinib) to benefit from Allist's mature commercial team and broad market coverage, while simultaneously allowing us to reduce operating costs associated with GAVRETO® (pralsetinib) commercialization and improving overall profitability.

  – In July 2025, the China NMPA approved the manufacturing localization application for GAVRETO® (pralsetinib, 100mg). Commencing in 2026, supply for the Chinese market will transition gradually from imported to locally manufactured product.

  – In August 2025, pralsetinib has passed the formal review for the 2025 NRDL negotiation.

  – GAVRETO® (pralsetinib) has been included in 11 of China's national guidelines for testing and treatment in multiple therapeutic areas, such as NSCLC and TC. In 2023, GAVRETO® (pralsetinib) was recommended by the 2023 Chinese Society of Clinical Oncology ("**CSCO**") NSCLC guideline, which recommended RET mutation gene testing and GAVRETO® (pralsetinib) in the treatment of RET positive NSCLC patients. In 2024, GAVRETO® (pralsetinib) as a treatment of stage IV RET fusion-positive NSCLC has been upgraded to a Level 1 recommendation in the 2024 CSCO NSCLC guideline.

- ***AYVAKIT® (avapritinib, KIT/PDGFRA inhibitor) advances commercialization with Hengrui's commercial partnership with domestic supply fully operational since February 2025***

  – AYVAKIT® (avapritinib), a FIC KIT/PDGFRA inhibitor, has been approved by the China NMPA for the treatment of adults with unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations. AYVAKIT® (avapritinib) has also been approved by the TFDA and the HK DoH for the treatment of patients with unresectable or metastatic PDGFRA D842V mutant GIST.

  – In July 2024, we entered into a commercial partnership with Jiangsu Hengrui Pharmaceuticals Co., Ltd. ("**Hengrui**") for the exclusive promotion rights of AYVAKIT® (avapritinib) in mainland China. The China NMPA has approved the manufacturing localization application in August 2024, and domestic supply has been launched in February 2025, with significant gross margin increase anticipated.

- We continued to improve the accessibility and affordability of AYVAKIT® (avapritinib). In 2023, AYVAKIT® (avapritinib) was included in the 2023 NRDL in China, for the treatment of adults with unresectable or metastatic GIST harboring the PDGFRA exon 18 mutation, including PDGFRA D842V mutations. The updated NRDL was implemented on January 1, 2025. The product has passed the formal review for the 2025 NRDL renewal negotiation.

- AYVAKIT® (avapritinib) is recommended by several authoritative guidelines, including the updated 2022 CSCO GIST guideline and the 2022 Chinese Guideline for Diagnosis and Treatment of Systemic Mastocytosis in Adults.

Clinical Stage Core Products

As of the date of this interim report, significant progress has been made across our product pipeline.

CS5001 (LCB71, ROR1 ADC) advances to Phase Ib stage with encouraging efficacy and safety profile

- CS5001 is a clinical-stage ADC targeting ROR1, featured with proprietary tumor-cleavable linker and pyrrolobenzodiazepine ("**PBD**") dimer prodrug. Only after reaching the tumor, the linker and prodrug are cleaved to release the PBD toxin, resulting in lethal DNA cross-links in cancer cells. The use of the linker plus PBD prodrug effectively helps address toxicity associated with traditional PBD payloads, leading to a better safety profile. CS5001 has demonstrated complete tumor suppression in several preclinical cancer models and demonstrated favorable serum half-life and pharmacokinetic characteristics. CS5001 is a promising candidate drug with precision treatment potential in both hematologic tumors and malignant solid tumors. Additionally, CS5001 utilizes site-specific conjugation for a precise drug antibody ratio ("**DAR**") of which enables homogeneous production and large-scale manufacturing. CS5001 is so far the first ROR1 ADC known to demonstrate clinical anti-tumor activity in both solid tumors and lymphomas.

- A global, multicenter, Phase Ia/Ib clinical trial of CS5001 is actively enrolling patients across the U.S., Australia and China. Phase Ib recruitment continues for monotherapy cohorts in aggressive and indolent advanced lymphomas with potential expansion into a Phase II single-arm registrational study. The Phase Ib study is also exploring therapeutic potential of CS5001 across different stages of DLBCL and solid tumors, including:

  - CS5001 + R-CHOP: First-line treatment for DLBCL patients who have not received prior systemic therapy.

  - CS5001 + SoC: For patients with relapsed or refractory DLBCL.

  - CS5001 Monotherapy: Targeting ROR1-expressing solid tumors.

  - CS5001 + Sugemalimab: Combination therapy for advanced solid tumors.

CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody): potential next-generation I/O backbone with smooth global Phase I/II clinical trial progress

- CS2009, a leading asset from the Company's Pipeline 2.0, is a potential FIC/BIC PD-1/VEGF/CTLA-4 trispecific antibody independently developed by CStone. It features balanced and monovalent PD-1 and CTLA-4 arms and a bivalent anti-VEGFA arm, which leads to potent multi-target synergy in the TME and preferential targeting of tumor tissue to reduce systemic toxicity. CS2009 preferentially blocks PD-1 and CTLA-4 on double-positive tumor-infiltrating T cells via avidity-driven engagement, while minimizing interference with CTLA-4 signaling in peripheral T cells, thus potentially offering enhanced efficacy with minimized systemic toxicity. In the tumor micro-environment ("**TME**"), CS2009's anti-PD-1 and anti-CTLA-4 activities are further enhanced significantly by crosslinking with VEGFA dimers that are upregulated in the TME.

- The global multicenter Phase I/II study is actively enrolling patients in Australia and China, with planned Phase II expansion into the U.S. The trial is progressing smoothly and is expected to exceed 100 patients by year-end.

  – In the Phase I dose-escalation study (6 cohorts, 1-45mg/kg, escalation and backfilling), CS2009 showed:

    - Favorable Safety:

      No DLT observed across all evaluated doses; well-tolerated in dozens of patients.

    - PK/PD Characteristics as Expected:

      Q3W dosing supported by linear pharmacokinetic with no accumulation;

      Robust T-cell activation/proliferation via PD-1/CTLA-4 blockade and potent and sustained VEGFA neutralization.

    - Broad and Deepening Antitumor Activity:

      Notable anti-tumor activity was observed across all doses, and the activity continued to enhance with prolonged follow-up;

      Activity demonstrated in multiple tumors, including cold tumors and PD-(L)1-refractory patients;

      Most patients remain on continued treatment.

  – Phase I data including safety, PK, PD, and antitumor activity will be presented at ESMO Congress in October 2025.

CS1002 (SHR-8068, anti-CTLA-4 antibody): strategic partnership with Hengrui in Greater China and active Phase III trial progress

- In November 2021, we entered an exclusive licensing agreement with Hengrui, which obtained the exclusive rights to research, development, registration, manufacturing, and commercialization of CS1002/SHR-8068 in Greater China. CStone retained all rights to develop and commercialize CS1002 outside of Greater China.

- Hengrui is actively advancing several major late-stage clinical trials for CS1002/SHR-8068 in multiple solid tumor types.

  – In March 2024, Hengrui initiated a Phase II/III trial evaluating CS1002/SHR-8068 in combination with adebrelimab and chemotherapy as a first-line treatment for advanced or metastatic non-squamous NSCLC.

- In September 2024, Hengrui commenced another Phase III trial comparing CS1002/SHR-8068 combined with adebrelimab and bevacizumab versus sintilimab combined with bevacizumab for the first-line treatment of advanced hepatocellular carcinoma ("**HCC**").

- In July 2025, Hengrui received IND acceptance for a Phase II study of CS1002/SHR-8068 in combination with adebrelimab, bevacizumab and apatinib for colorectal cancer ("**CRC**").

- In August 2025, Hengrui registered a randomized, open-label, controlled, multicenter phase III study to evaluate CS1002/SHR-8068 in combination with adebrelimab and platinum-based chemotherapy, compared to tislelizumab combined with platinum-based chemotherapy, as first-line treatment for NSCLC with negative PD-L1 expression (TPS＜1%).

Nofazinlimab (CS1003, anti-PD-1 antibody) final analysis readout

- CS1003-305 study is a global, multicenter, randomized, double-blind Phase III registrational trial conducted across 74 sites worldwide. The study evaluates the efficacy and safety of the anti-PD-1 monoclonal antibody nofazinlimab (CS1003) in combination with LENVIMA® (lenvatinib) versus placebo in combination with lenvatinib as first-line treatment for patients with unresectable or metastatic HCC. The primary endpoint was OS. Key secondary endpoints included PFS and ORR as assessed by Blinded Independent Central Review ("**BICR**").

- In July 2025, we updated the final analysis which demonstrated a clinical compelling trend in OS for the nofazinlimab-lenvatinib combination compared to placebo-lenvatinib, indicating meaningful patient benefit despite not reaching statistical significance. In addition, clinically meaningful improvements in PFS and ORR were achieved, with outcomes numerically competitive against established therapeutic benchmarks. Nofazinlimab demonstrated a manageable safety profile, consistent with prior research findings and marketed PD-(L)1 antibodies, and no new safety signals were observed. We will engage with regulatory authorities to explore the registration pathway for this combination therapy.

Preclinical/IND-enabling candidates

We maintains our commitment to pioneering next-generation anti-cancer therapeutics, including multispecific antibodies, ADCs and more. Meanwhile, our early research portfolio has been expanded to encompass autoimmune and inflammatory diseases.

Key pipeline advancements include:

- **In-house proprietary ADC technology platform:** CStone is actively advancing next-generation linker technology to improve systematic stability and tumor selectivity of ADCs. Our proprietary tandem-cleavable β-glucuronide linker demonstrates:

  - Enhanced hydrophilicity improving circulating stability of the entire molecule.

  - Tumor selective payload release through tandem cleavage mechanism.

  - Clinical validated semi-stochastic conjugation with maleimide function group for manufacturability.

  This in-house proprietary ADC technology platform optimizes ADC safety/efficacy profiles, broadens target compatibility, and supports multiple ADC candidates in CStone's Pipeline 2.0, including CS5005 (SSTR2 ADC), CS5008 (DLL3&SSTR2 bispecific ADC), CS5006 (ITGB4 ADC), CS5007 (EGFR&HER3 bispecific ADC), CS5009 (B7H3/PD-L1 bispecific ADC), etc.

- **Core ADC pipeline:**

  - **CS5007 (EGFR/HER3 bispecific ADC):** CS5007 is composed of EGFR/HER3 bispecific antibody backbone (CS2011), a hydrophilic β-glucuronide linker, and exatecan. It is designed to address tumor heterogeneity by simultaneously targeting EGFR and HER3, with strong affinities to EGFR+ and/or HER3+ tumor cells. It demonstrates potent antitumor efficacy and favorable safety/PK profiles. CS5007 is positioned as a best-in-class candidate for precision oncology across multiple solid tumors, including NSCLC, SCCHN, CRC, etc.

  - **CS5005 (SSTR2 ADC) and CS5008 (SSTR2/DLL3 bispecific ADC):** CS5005 is composed of CStone's proprietary anti-SSTR2 antibody (high affinity and selectivity), hydrophilic β-glucuronide linker, and exatecan (clinically validated topoisomerase I inhibitor). It represents a promising therapeutic approach for SSTR2+ solid tumors including neuroendocrine neoplasms ("**NENs**") and small cell lung cancer ("**SCLC**"), and demonstrates potent antigen-dependent tumor growth inhibition. CS5008 is a novel DLL3/SSTR2 bispecific ADC using CStone's proprietary antibody and linker payload. Through dual targeting of SSTR2 and DLL3, which are frequently co-expressed in NENs, SCLC and other malignancies, CS5008 aims to overcome tumor heterogeneity, a challenge inherent to mono-targeting therapies.

  - **CS5006 (ITGB4 ADC):** CS5006 is a FIC ADC against novel pan-tumor target ITGB4, a transmembrane protein that exclusively pairs with integrin α6 (ITGA6) to form α6β4 heterodimer. Robust in vitro and in vivo evidence supports its clinical development. This molecule targets diverse indications including NSCLC, squamous cell carcinoma of head and neck ("**SCCHN**"), CRC, etc.

- **Autoimmune and inflammatory multi-specific antibodies:**

  - **CS2013 (BAFF/APRIL bispecific antibody):** CS2013 features a differentiated molecular design to simultaneously block BAFF and APRIL, which are two essential ligands for B cell/plasma cell development and survival. Preclinical studies have demonstrated synergistic effects and exceptional stability that supports the development of subcutaneous formulations. Furthermore, it exhibits superior PK profiles to fusion proteins, including an extended half-life that potentially enables reduced dosing frequency. CS2013 targets B-cell-mediated autoimmune diseases, such as systemic lupus erythematosus ("**SLE**"), rheumatoid arthritis ("**RA**"), IgA nephropathy ("**IgAN**"), etc.

  - **CS2015 (OX40L/TSLP bispecific antibody):** CS2015, a potential FIC bispecific antibody targeting both OX40L (a key ligand on immune effector cells) and TSLP (a critical alarmin secreted by epithelial cells), potently blocks these two key ligands in Th2-mediated inflammatory diseases, such as atopic dermatitis ("**AD**"), asthma and chronic obstructive pulmonary disease ("**COPD**"). Robust preclinical PK data have further confirmed an extended half-life and feasibility for subcutaneous administration.

CAUTIONARY STATEMENT REQUIRED BY RULE 18A.08(3) OF THE LISTING RULES: WE MAY NOT BE ABLE TO ULTIMATELY DEVELOP AND MARKET ANY OF OUR PIPELINE PRODUCTS, SUCCESSFULLY.

Business Development and Strategic Partnerships

Our business development team plays a pivotal role in driving strategic growth for our organization. This encompasses expanding the commercialization of our in-market drugs, strengthening our clinical-stage pipeline with potential FIC and BIC molecules, and acquiring innovative technologies that enhance our research and development efforts. As of the date of this interim report, we have established strong strategic partnerships with leading companies, including Pfizer, Sanofi, Hengrui, 3SBio Inc., Allist, Ewopharma, Pharmalink, SteinCares and Gentili, etc.

Regarding our in-market products in mainland China, we executed an exclusive commercialization agreement with Allist for GAVRETO® in November 2023. Subsequently, we entered into a strategic partnership with Hengrui in July 2024 to commercialize AYVAKIT®. Under both agreements, CStone retains all other rights including development, registration, manufacturing and distribution, etc.

For the global commercialization of our anti-PD-L1 antibody sugemalimab (CEJEMLY®), we continue to establish strategic partnerships across key regions. In May 2024, we secured a commercial collaboration with Ewopharma, covering Switzerland and 18 Central Eastern European countries ("**CEE**") countries. In November 2024, we further expanded our global footprint through a strategic alliance with Pharmalink for Middle East and North Africa ("**MENA**") region and South Africa. In January 2025, we formed a commercialization partnership with SteinCares for LATAM region. In July 2025, we signed an exclusive license agreement with Gentili for Western Europe and the U.K..

Beyond these initiatives, we remain actively engaged with potential partners to explore a range of opportunities aimed at accelerating value creation. These include in-licensing, out-licensing, and strategic partnerships.

Note: AYVAKIT® and associated logos are trademarks of Blueprint Medicines Corporation. GAVRETO® and associated logos are trademarks of Blueprint Medicines Corporation outside of the U.S. In July 2025, Sanofi publicly announced the successful completion of its US$9.5 billion acquisition of Blueprint Medicines Corporation.

FINANCIAL REVIEW

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

Six months ended June 30, 2025 Compared to Six months ended June 30, 2024

	For the six months ended June 30,	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Revenue	**49,451**	254,165
Cost of revenue	**(142,241)**	(82,136)
Gross (loss) profit	**(92,790)**	172,029
Other income	**9,315**	14,824
Other gains and losses	**4,566**	12,884
Research and development expenses	**(105,166)**	(66,248)
Selling and marketing expenses	**(35,654)**	(62,769)
Administrative expenses	**(43,546)**	(46,672)
Finance costs	**(6,908)**	(8,349)
(Loss) profit for the period	**(270,183)**	15,699
Other comprehensive income (expense):		
Item that may be reclassified subsequently to profit or loss:		
Exchange differences arising on translation of foreign operations	**269**	(11)
Total comprehensive (expense) income for the period	**(269,914)**	15,688
Non-IFRS measures:		
Adjusted (loss) profit for the period	**(265,099)**	10,810

Revenue. Our revenue was RMB49.4 million for the six months ended June 30, 2025, representing a decrease of RMB204.8 million or 80.5% compared to RMB254.2 million for the six months ended June 30, 2024. The revenue is composed of RMB20.2 million from sales of pharmaceutical products (avapritinib, pralsetinib), RMB17.9 million from license fee income and RMB11.3 million from royalty income of sugemalimab. (1) Revenue from sales of pralsetinib decreased substantially period-on-period, which is primarily due to price adjustments of pralsetinib in preparation for the NRDL negotiation and related one-off channel compensation. If included in NRDL, benefit from sales ramp up of pralsetinib in 2026 and beyond is expected to overweigh short-term negative impact on revenue. (2) License fee income also decreased substantially period-on-period, primarily due to the fact that we received a strong contribution from a one-time milestone payment for sugemalimab gastric cancer approval in China in the first half of 2024. No material out-licensing arrangement was entered into during the first half of 2025, however, the major out-licensing agreement with Gentili in July 2025 is expected to contribute to license fee income for the second half of 2025.

Cost of Revenue. Our cost of revenue was RMB142.2 million for the six months ended June 30, 2025, representing an increase of RMB60.1 million from RMB82.1 million for the six months ended June 30, 2024, primarily due to inventory write-downs charged to cost of revenue and cost associated with an early billing of pralsetinib supply under the Patient Assistance Program covering the period through the first half of 2026 to mitigate customs clearance risks amid trade uncertainties.

Other Income. Our other income decreased by RMB5.5 million from RMB14.8 million for the six months ended June 30, 2024 to RMB9.3 million for the six months ended June 30, 2025. This was primarily due to less bank and other interest income.

Other Gains and Losses. Our other gains and losses decreased by RMB8.3 million from RMB12.9 million for the six months ended June 30, 2024 to RMB4.6 million for the six months ended June 30, 2025. This decrease was primarily due to a net loss on fair value changes of financial assets measured at FVTPL.

Research and Development Expenses. Our research and development expenses increased by RMB39.0 million from RMB66.2 million for the six months ended June 30, 2024 to RMB105.2 million for the six months ended June 30, 2025. This increase was primarily attributable to an increase of RMB35.9 million in milestone fee and third party contracting cost for different phases of our clinical trials from RMB15.4 million for the six months ended June 30, 2024 to RMB51.3 million for the six months ended June 30, 2025.

	For the six months ended June 30,	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Milestone fee and third party contracting cost	**51,315**	15,363
Employee cost	**35,895**	34,173
Depreciation and others	**17,956**	16,712
Total	**105,166**	66,248

Administrative Expenses. Our administrative expenses decreased by RMB3.2 million from RMB46.7 million for the six months ended June 30, 2024 to RMB43.5 million for the six months ended June 30, 2025. This decrease was primarily attributable to a decrease of RMB2.7 million in depreciation and amortization from RMB5.3 million for the six months ended June 30, 2024 to RMB2.6 million for the six months ended June 30, 2025.

	For the six months ended June 30,	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Employee cost	**24,359**	23,860
Professional fees	**13,345**	13,351
Depreciation and amortization	**2,636**	5,278
Rental expenses	**484**	1,500
Others	**2,722**	2,683
Total	**43,546**	46,672

Selling and Marketing Expenses. Our selling and marketing expenses decreased by RMB27.1 million from RMB62.8 million for the six months ended June 30, 2024 to RMB35.7 million for the six months ended June 30, 2025. This decrease was primarily attributable to a decrease of RMB19.6 million in channel service fee and others from RMB53.5 million for the six months ended June 30, 2024 to RMB33.9 million for the six months ended June 30, 2025.

	For the six months ended June 30,	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Employee cost	**1,713**	9,318
Channel service fee and others	**33,941**	53,451
Total	**35,654**	62,769

Finance Costs. The finance costs decreased by RMB1.4 million from RMB8.3 million for the six months ended June 30, 2024 to RMB6.9 million for the six months ended June 30, 2025, primarily due to a decrease in interest on bank borrowings.

Non-IFRS Measures

To supplement the Group's condensed consolidated financial statements, which are presented in accordance with the IFRS, the Company also uses adjusted (loss) profit for the period and other adjusted figures as additional financial measures, which are not required by, or presented in accordance with, the IFRS. The Company believes that these adjusted measures provide useful information to shareholders and potential investors in understanding and evaluating the Group's consolidated results of operations in the same manner as they help the Company's management.

Adjusted (loss) profit for the period represents the (loss) profit for the period excluding the effect of certain noncash items and one-time events, namely the share-based payment expenses. The term adjusted (loss) profit for the period is not defined under the IFRS. The use of this non-IFRS measure has limitations as an analytical tool, and you should not consider it in isolation from, or as substitute for analysis of, the Group's results of operations or financial condition as reported under IFRS. The Company's presentation of such adjusted figure may not be comparable to a similarly titled measure presented by other companies. However, the Company believes that this and other non-IFRS measures are reflections of the Group's normal operating results by eliminating potential impacts of items that the management do not consider to be indicative of the Group's operating performance, and thus facilitate comparisons of operating performance from period to period and company to company to the extent applicable.

The table below sets forth a reconciliation of the (loss) profit to adjusted (loss) profit during the periods indicated:

	For the six months ended June 30,	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
(Loss) profit for the period	**(270,183)**	15,699
Added:		
Share-based payment expenses	**5,084**	(4,889)
Adjusted (loss) profit for the period	**(265,099)**	10,810

The table below sets forth a reconciliation of the research and development expenses to adjusted research and development expenses during the periods indicated:

	For the six months ended June 30,	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Research and development expenses for the period	**(105,166)**	(66,248)
Added:		
Share-based payment expenses	**3,077**	(4,770)
Adjusted research and development expenses for the period	**(102,089)**	(71,018)

The table below sets forth a reconciliation of the administrative and selling and marketing expenses to adjusted administrative and selling and marketing expenses during the periods indicated:

	For the six months ended June 30,	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Administrative and selling and marketing expenses for the period	**(79,200)**	(109,441)
Added:		
Share-based payment expenses	**2,007**	(119)
Adjusted administrative and selling and marketing expenses for the period	**(77,193)**	(109,560)

Employees and Remuneration Policies

The following table sets forth a breakdown of our employees as of June 30, 2025 by function:

Function	Number of employees	% of total number of employees
Research and Development	83	63.36
Sales, General and Administrative	48	36.64
Total	131	100.0

As of June 30, 2025, we had 93 employees in Shanghai, 9 employees in Beijing, 21 employees in Suzhou and 8 employees in other regions of the PRC and overseas. Our employees' remuneration comprises salaries, bonuses, employee provident fund, social security contributions and other welfare payments. In accordance with applicable Chinese laws, we have made contributions to social security insurance funds (including pension plans, medical insurance, work-related injury insurance, unemployment insurance and maternity insurance) and housing funds for our employees.

Liquidity and Financial Resources

The Group has always adopted a prudent treasury management policy. The Group has taken a multi-source approach to fund our operations and meet development demands for capital, including service and milestone and upfront payments from our collaboration partners, bank borrowings, investments from other third parties and proceeds from our listing on the Stock Exchange.

On February 26, 2019, 186,396,000 Shares of US$0.0001 each were issued at a price of HK$12.00 per Share in connection with the Company's initial public offering ("**IPO**") on the Stock Exchange. The proceeds of HK$146,294.76 representing the par value, were credited to the Company's share capital. The remaining proceeds of RMB2,090.16 million (before deduction of the expenses relating to the Company's IPO) were credited to the share premium account. The translation from US$ to HK$ is made at the exchange rate set forth in the H.10 weekly statistical release of the Federal Reserve System of the United States as of February 26, 2019.

On September 30, 2020 (before trading hours), the Company entered into the share subscription agreement with Pfizer, pursuant to which Pfizer has conditionally agreed to subscribe for an aggregate of 115,928,803 subscription shares at the subscription price of approximately HK$13.37 per Share. The gross proceeds from the allotment and issue of the subscription shares were approximately US$200.0 million (equivalent to approximately RMB1,355.9 million).

On February 15, 2023, the Company completed the placing of 84,800,000 placing shares by a placing agent to not less than six placees at the placing price of HK$4.633 per placing share, representing 6.61% of the issued share capital of the Company as enlarged by the allotment and issue of the placing shares immediately upon completion of the placing. The Company received net proceeds from the placing, after deducting the placing commission and other related expenses and professional fees, of approximately HK$389.07 million (equivalent to approximately RMB338.12 million).

On April 10, 2025, the Company completed the placing of 80,000,000 placing shares by a placing agent to not less than six placees at the placing price of HK$2.933 per placing share, representing 5.86% of the issued share capital of the Company as enlarged by the allotment and issue of the placing shares immediately upon completion of the placing. The Company received net proceeds from the placing, after deducting the placing commission and other related expenses and professional fees, of approximately HK$232.29 million (equivalent to RMB215.82 million).

At June 30, 2025, our cash and cash equivalents and time deposits were RMB652.8 million, as compared to RMB672.9 million as of December 31, 2024. The decrease was mainly due to the payment of research and development expenses, payroll and purchase of inventories. The cash and cash equivalents were mainly denominated in RMB, USD and HKD.

Gearing Ratio

Gearing ratio is calculated using total liabilities divided by total assets and multiplied by 100%. At June 30, 2025, our gearing ratio was 73.6% (December 31, 2024: 73.9%).

Charge on Assets

At June 30, 2025, the Group did not pledge any assets (December 31, 2024: Nil).

OTHER FINANCIAL INFORMATION

Significant Investments, Material Acquisitions and Disposals

As at June 30, 2025, we did not hold any significant investments and there had been no material acquisitions and disposals by the Group. As at the date of this interim report, we have no specific future plan for material investments or capital assets, as well as material acquisitions or disposals of subsidiaries, associates and joint ventures.

Foreign Exchange Risk

Our financial statements are expressed in RMB, but certain of our cash and cash equivalents, restricted bank deposits, time deposits, other receivables, financial assets measured at FVTPL and trade and other payables are denominated in foreign currencies, and are exposed to foreign currency risk. We currently do not have a foreign currency hedging policy. However, the management of the Group monitors foreign exchange exposure and will consider hedging significant foreign currency exposure should the need arise.

Bank Loans and Other Borrowings

As at June 30, 2025, the Group's bank borrowings were RMB363,200,000, all bank borrowings denominated in RMB.

Contingent Liabilities

As at June 30, 2025, the Group did not have any material contingent liabilities (December 31, 2024: Nil).

DIRECTORS

Executive Director

Dr. Jianxin Yang (楊建新), M.D., Ph.D., aged 61, is our Chief Executive Officer, Executive Director, President of Research and Development, Chairman of the Strategy Committee and an authorized representative of the Company and was re-elected as an Executive Director on June 21, 2023. Dr. Yang was our founding Chief Medical Officer and Senior Vice President of Clinical Development from December 2016 to August 2022. Currently, he is responsible for the overall operation strategic planning and business operation of our Group. Dr. Yang also acts as a director in certain of our subsidiaries.

Dr. Yang is a seasoned biopharma leader with 30+ years of experience spanning drug discovery, translational research, clinical development, and commercialization in the U.S. and China. Throughout his career, Dr. Yang has made significant contributions to the successful development of several anticancer drugs. At CStone, he successfully brought 4 novel drugs to market – Sugemalimab, Avapritinib, Pralsetinib, and Ivosidenib. Sugemalimab was approved in the EU and the UK in 2024, marking the first successful international entry of a domestically developed PD-L1 inhibitor from China. He has built CStone into a preferred global partner for bringing innovative medicines to Greater China and enabled China biopharmas to access global markets.

Prior to joining us, he served as the Senior Vice President and Head of Clinical Development at BeiGene, Ltd. (NASDAQ: BGNE, HKSE: 6160, the Star Market of SHSE: 688235) from July 2014 to December 2016. He built the clinical team and led global development/operations for their diverse oncology pipeline (PD1, BTKi, PARPi, RAFi), conducting 10+ trials from FIH to pivotal studies and approvals.

Prior to joining BeiGene, Ltd., Dr. Yang served in several roles including as an Oncology Medical Director at Covance Inc. from September 2011 to July 2014. He served as Senior Principal Scientist for tumor biomarkers in Pfizer Inc. from October 2004 to August 2011, and served as a Research Scientist in the cancer genomics division at Tularik Inc. from September 1998 and September 2004 (acquired by Amgen Inc. in 2004).

Dr. Yang is an author of 80+ publications and conference reports, including 10+ articles in JAMA, Nature Medicine, The Lancet Oncology, JCO, Nature Cancer, Clinical Cancer Research, among others. He is an inventor of 15 patents.

Dr. Yang received a bachelor's degree in medicine from Xianning Branch of Hubei Medical College (湖北醫學院咸寧分院), (currently known as Hubei Institute of Science and Technology (湖北科技學院) in Hubei, China in July 1985 and a master's degree in pathophysiology from Nanjing Medical College (南京醫學院), (currently known as Nanjing Medical University (南京醫科大學)) in Nanjing, China in July 1988. He then received his Ph.D. training in molecular biology with Nobel Laureates Drs. Michael S. Brown and Joseph L. Goldstein at the University of Texas Southwestern Medical Center at Dallas, U.S. in June 1995. He conducted his postdoctoral training in chemical biology with Dr. Stuart L. Schreiber at Harvard University in the United States from 1995 to 1998.

Non-executive Directors

Dr. Wei Li (李偉), Ph.D. aged 53, is our Chairman of Board. He has been our Director since December 2015 and was re-designated as a non-executive Director on October 29, 2018, and was re-elected as a non-executive Director on June 25, 2025. Dr. Li took up the role of Chairman and the chairman of the Nomination Committee on May 31, 2022. Dr. Wei Li is also a member of the Compensation Committee. Dr. Li also acts as a director in certain of our subsidiaries.

Dr. Li has over 20 years of experience in the biotech industry. He serves as a partner of Creacion Ventures since April 2020 and the managing partner of 6 Dimensions Capital, L.P. since October 2017 and is a founding partner and the managing partner of WuXi Healthcare Ventures II, L.P. since July 2015. Dr. Li served as an executive director of Ocumension Therapeutics (歐康維視生物), a company listed on the Stock Exchange (stock code: 1477), from April 2018 to July 2021 and re-designated as a non-executive director since July 2021. Dr. Li resigned as non-executive director of Ocumension Therapeutics with effect from January 16, 2025.

During his scientific research career, Dr. Li has first-authored numerous scientific publications in journals including Science, Proceedings of the National Academy of Sciences, and Journal of Biological Chemistry.

Dr. Li received a Ph.D. in chemistry from Harvard University in the United States in November 1998, and master's degree in business administration ("**MBA**") from the J. L. Kellogg School of Management at Northwestern University in the United States in June 2003. He graduated with a bachelor of science in chemical physics from the University of Science and Technology of China (中國科學技術大學) in Anhui, China in July 1993.

Mr. Kenneth Walton Hitchner III, aged 65, was appointed as our non-executive Director with effect from December 10, 2021 and was re-elected as a non-executive Director on June 18, 2024. Mr. Hitchner is a member of the Investment Committee.

Mr. Hitchner has more than 30 years of experience in corporate finance. He had served as the Chairman and Chief Executive Officer of The Goldman Sachs Group, Inc. in Asia Pacific Ex-Japan before his retirement in 2019. He was also a member of Goldman Sachs' Management Committee and co-chaired its Asia Pacific Management Committee.

Mr. Hitchner has served as an independent non-executive director of Provident Acquisition Corp., a company listed on NASDAQ (stock code: PAQC), from January 2021 to October 2022. He ceased to serve as a senior advisor to a leading global life sciences investor Valiance Asset Management in December 2022. During the period from 2013 to 2017, Mr. Hitchner had served as President of Goldman Sachs in Asia Pacific Ex-Japan. Prior to relocating to Hong Kong, he was global head of Goldman Sachs' Healthcare Banking Group and global co-head of its Technology, Media and Telecom Group. He was named managing director in 2000 and partner in 2002. He became head of the global medical device banking practice in 1998 and head of the global pharmaceutical banking practice in 2001. He began his career with Goldman Sachs' Corporate Finance Department in 1991.

Mr. Hitchner has been serving as an independent non-executive director of WuXi Biologics (Cayman) Inc., a company listed on the Main Board of the Stock Exchange (stock code: 2269), since June 2020. Mr. Hitchner has been serving as a director of the alternative investment management firm Elements Advisors SPV since May 2020. He has joined Global Advisory Board of the global early-stage venture capitalist Antler since January 2021. He has also been serving as a senior advisor of WuXi AppTec Co., Ltd.* (無錫藥明康德新藥開發股份有限公司), a company listed on the Shanghai Stock Exchange (stock code: 603259) and the Main Board of the Stock Exchange (stock code: 2359) ("**WuXi AppTec**"), since February 2020. Mr. Hitchner has also been serving as the chairman of the board of HH&L Acquisition Co., a company listed on the New York Stock Exchange (stock code: HHLA), since February 11, 2021. Mr. Hitchner has also been serving as the chairman of the board of two UK private healthcare companies, Cydar Medical and Sphere Fluidics, since February 2023 and May 2023, respectively. He has also been serving as an independent non-executive director of WuXi XDC Cayman Inc., a company listed on the Main Board of the Stock Exchange (stock code: 2268), since November 2024.

Mr. Hitchner obtained a bachelor's degree in arts from the University of Colorado in 1982 and a master's degree in MBA as a merit fellow from Columbia University Business School in 1992.

Mr. Edward Hu (胡正國), aged 62, was appointed as our non-executive Director on July 9, 2021 and was re-elected as a non-executive Director on June 18, 2024. He is a member of the Strategy Committee and the chairman of the Investment Committee.

Mr. Hu severed as the vice chairman, the global chief investment officer and an executive director of WuXi AppTec and he was primarily responsible for the overall business and management of WuXi AppTec before his retirement with effect from July 31, 2025. Mr. Hu joined WuXi AppTec in August 2007 and served as an executive director from March 2017 to July 2025. Mr. Hu served as a co-chief executive officer of WuXi AppTec from August 2018 to May 2020. He served as the chief financial officer from March 2016 to January 2019.

- From July 2022 to September 2024, he served as a non-executive director of CANbridge Pharmaceuticals Inc., a company listed on the Main Board of the Stock Exchange (stock code: 1228).

- From July 2022 to February 2023, he served as a director of Ambrx Biopharma Inc., a company listed on NASDAQ (stock code: AMAM).

- From February 2014 to June 2021, he served as a non-executive director of WuXi Biologics (Cayman) Inc., a company listed on the Main Board of the Stock Exchange (stock code: 2269) and was primarily responsible for providing guidance on the business strategy and financial management.

- From May 2018 to March 2021, he served as a director of Viela Bio Inc., a company listed on NASDAQ (stock code: VIE).

- From August 2007 to December 2015, he served as the chief financial officer and chief operating officer of WuXi PharmaTech (Cayman) Inc., a company previously listed on the New York Stock Exchange and was responsible for the financial and operational management.

- From October 2000 to July 2007, he served on various roles to become a senior vice president and chief operating officer of Tanox Inc., a biopharmaceutical company previously listed on NASDAQ (stock code: TNOX, acquired by Genentech Inc. in August 2007) and primarily engaged in discovering and developing antibody therapeutic drugs, and was responsible for company operations, quality control, finance and information technology.

- From April 1998 to October 2000, he served as a business planning manager of Biogen Inc., a global biotechnology company listed on NASDAQ (stock code: BIIB) and primarily engaged in developing, marketing and sales of biopharmaceuticals for neurologic and immune diseases, and was responsible for business planning and budget management of its research and development division.

- From May 1996 to December 1998, he served as a senior financial analyst of Merck, and was responsible for financial planning and analysis.

Mr. Hu obtained a bachelor's degree in physics from Hangzhou University, currently known as Zhejiang University (浙江大學) in the PRC in July 1983. He also obtained a master's degree in chemistry and a master's degree of business administration from Carnegie Mellon University in the United States in May 1993 and May 1996, respectively.

Independent Non-executive Directors

Mr. Ting Yuk Anthony Wu (胡定旭), GBS, JP, aged 71, has been an INED since February 14, 2019, and was re-elected as an INED on June 18, 2024. Mr. Wu is the chairman of the Compensation Committee and a member of the Audit Committee and the Nomination Committee.

Mr. Wu has been appointed as an independent non-executive director of Hui Xian Real Estate Investment Trust (匯賢產業信託) (stock code: 87001) since November 2022. Since March 2019, Mr. Wu has been the chairman and a non-executive director of Clarity Medical Group Holding Limited (清晰醫療集團控股有限公司), a company listed on the Stock Exchange (stock code: 1406) on February 18, 2022. Mr. Wu has been an independent non-executive director of Sing Tao News Corporation Limited (星島新聞集團有限公司), a company listed on the Stock Exchange (stock code: 1105) since June 2021. He has been an independent non-executive director of China Resources Medical Holdings Company Limited (華潤醫療控股有限公司), a company listed on the Stock Exchange (stock code: 1515) since August 2018 and chairman of the board of directors from August 2018 to April 2021. He has been an independent non-executive director of Power Assets Holdings Limited (電能實業有限公司), a company listed on the Stock Exchange (stock code: 0006) since June 2014. He has been an independent non-executive director and chairman of the board of VenusMedtech (Hangzhou) Inc. (杭州啟明醫療器械股份有限公司), a company listed on the Stock Exchange (stock code: 2500) since July 2019 and December 2023, respectively. He has been an independent non-executive director of Ocumension Therapeutics (歐康維視生物), a company listed on the Stock Exchange (stock code: 1477) since June 2020.

Mr. Wu is a board member of the West Kowloon Cultural Authority and the HK University of Science and Technology. He is a Fellow of the Chinese University of HK, a distinguished visiting professor of Tsinghua Wah University, honorary professor of the Peking Union University Hospital, the Baptist University Chinese Medicine Faculty and the HK Chinese University Medical Faculty. He is also the Honorary Chairman of The Institute of Certified Management Accountants (Australia) Hong Kong Branch.

Mr. Wu was admitted as a member of the Institute of Chartered Accountants in England and Wales in November 1979 and became a fellow in October 1990. He was also admitted as a member of the Hong Kong Institute of Certified Public Accountants and the Association of Chartered Certified Accountants.

Mr. Wu was appointed by the Government of Hong Kong as Justice of the Peace and awarded Gold Bauhinia Star in 2004 and 2008, respectively. Mr. Wu finished a Foundation Course in Accountancy in Teesside Polytechnic in the United Kingdom in July 1975.

Ms. Yip Betty Ho (何曄), aged 56, has been an INED since December 30, 2024 and was re-elected as INED on June 25, 2025. Ms. Ho is the chairperson of the Audit Committee, a member of the Compensation Committee, the Nomination Committee, the Strategy Committee and the Investment Committee.

Ms. Ho has extensive experience in public companies, healthcare, merger and acquisitions, private equity across a wide range of industries. Prior to joining the Company, Ms. Ho served as chief strategy officer at DHgate Holdings Limited, a company principally engaged in cross-border e-commerce in China from April 2020 to March 2024. Ms. Ho also served as an independent non-executive director at Ezisurg Medical Co., Ltd. from May 2022 to September 2023.

Ms. Ho served as chief financial officer and director of Phoenix New Media Limited, a company listed on the New York Stock Exchange (NYSE: FENG), from October 2013 to November 2019 and from November 2017 to November 2019, respectively, preceded by her role as chief financial officer at Rock Mobile Corporation since January 2012. Ms. Ho served as chief financial officer at A8 New Media Group Limited (formerly known as A8 Digital Music Holdings Limited), a company formerly listed on The Stock Exchange of Hong Kong Limited (HKEX: 800), from July 2007 to January 2011. Ms. Ho was appointed as executive director and redesignated as non-executive director of the board of A8 New Media Group Limited from November 2007 to December 2010 and from December 2010 to May 2011, respectively.

Prior to that, Ms. Ho held various management positions in audit and investment, including chief financial officer and vice president of corporate development at Lorenzo Jewelry Limited, a wholly-owned subsidiary of LJ International, Inc. (NASDAQ: JADE), from 2001 to 2007. Before that, she was an auditor at Arthur Andersen & Co.

Ms. Ho obtained her bachelor's degree in commerce from the University of Toronto in Canada in June 1993. She also completed the Stanford Executive Leadership Program and the Stanford Director's College in the United States through a hybrid of classes in person and distance learning in May 2018. Ms. Ho has been a member of the American Institute of Certified Public Accountants since September 1997.

Mr. Kenneth Howard Jarrett, aged 72, has been an INED since September 23, 2025 and a member of the Audit Committee and the Strategy Committee.

Mr. Jarrett has over 40 years of experience in government and business relations, strategic planning and key relationship building. Mr. Jarrett has been serving as senior advisor of Albright Stonebridge Group, a strategic advisory firm based in Washington D.C. in the U.S. since January 2019. Prior to joining the Company, Mr. Jarrett served as independent director and members of the audit, compensation and nomination/governance committee of Wanda Sports Group Company Limited (a company delisted from Nasdaq in February 2021) from October 2019 to January 2021. During his extensive diplomatic career, Mr. Jarrett held several key positions across U.S. consulates, embassies and the private sector including president of the American Chamber of Commerce in Shanghai from September 2013 to December 2018, Greater China chairman of APCO Worldwide, a public affairs and strategic communication consultancy firm in the U.S. from October 2008 to July 2013, Consul General of the U.S. Consulate General in Shanghai from July 2005 to August 2008 and Deputy Consul General of the U.S. Consulate General in Hong Kong from July 2001 to July 2004. Prior to that, Mr. Jarrett served as chief of the Political Unit of the U.S. Embassy in Singapore, senior political officer of the Office of Israeli Affairs of the Department of State in the U.S., chief of the Political Section of the U.S. Embassy in Beijing and director for Asian Affairs of the National Security Council in Washington D.C. from 1991 to 2001.

Mr. Jarrett brings extensive board-level experience from services with universities and a range of public sector organizations. He has been serving as member of the National Committee on U.S.-China Relations, a non-profit organization promoting understanding between the U.S. and China, since 2009 and as trustee of the Yale-China Association since 2025. Previously, Mr. Jarrett served as member of Cornell University China Advisory Council from 2016 to 2024, board member of the American Chamber of Commerce in Shanghai from 2011 to 2013, chairman of the board of the USA Pavilion at the Shanghai World Expo from 2009 to 2012 and board member of the Hong Kong International School from 2001 to 2004.

Mr. Jarrett obtained his bachelor's degree in history from Cornell University in the U.S. in May 1975. He obtained his master's degree in East Asian studies, Chinese history from Yale University in the U.S. in December 1979 and a master's degree in national security studies from National War College in Washington D.C. in May 1997.

SENIOR MANAGEMENT

Dr. Jianxin Yang (楊建新), M.D., Ph.D., aged 61, has been our CEO and president of research and development since August 25, 2022 and March 27, 2024, respectively. For further details, please refer to "Directors – Executive Director" in this section.

Mr. Michael J. Choi, MBA, aged 50, joined our Company in May 2021 and he has been our Chief Business and Strategy Officer since September 2022. In this role, he is responsible for business development, alliance management and corporate strategy.

Mr. Choi is an accomplished business executive with over 25 years of experience in the life science industry. Prior to joining us Mr. Choi was VP, Head of Business Development at Sun Pharma Advanced Research Corporation (SPARC) from September 2019 to April 2021. In this role, he led business development, commercial strategy and investor relations and oversaw the strategy and operations of SPARC as a member of the Executive Leadership Team. From March 2011 to July 2019, Mr. Choi served at Pfizer, Inc. in various business development roles including most recently as Business Alliance Lead for China, Japan, Asia Pacific, Latin-America and Canada at Pfizer Essential Health. While at Pfizer, Mr. Choi completed over 40 transactions across 6 continents. From April 2009 to March 2011, Mr. Choi served as the Strategy Leader for the Molecular and Cell Biology business unit at Life Technologies (now Thermo Fisher). Mr. Choi started his career as a Research Associate at the Columbia University College of Physicians and Surgeons before starting his business career as a strategy focused Management Consultant at various firms such as PricewaterhouseCoopers – Management Consulting Services, Envision Consulting Group (now IQVIA), and Frankel Group (now Oliver Wyman).

Mr. Choi obtained his MBA in Finance and Economics from Columbia Business School in New York City in May 2004 and Bachelor of Arts in History with a pre-medical concentration from Columbia College in New York City in May 1996.

Dr. Qingmei Shi (史青梅), M.D., Ph.D., aged 49, joined our Company in May 2019, and currently is our senior vice president and Chief Medical Officer. In her current role, Dr. Shi oversees the clinical development of our assets from IND until NDA approval. Additionally, she leads the medical/science, pharmacovigilance, regulatory affairs, quality assurance and biometrics functions to support progression of clinical development. Prior to this role, Dr. Shi was our head of clinical development and mainly responsible for the clinical development of our late-stage assets. Dr. Shi also acts as a director in one of our subsidiary.

With over 20 years of experience in clinic and the pharmaceutical industry, Dr. Shi brings extensive expertise in oncology and hematology therapeutic areas. Prior to joining our company, she served as a senior medical director at Covance Pharmaceutical Research and Development (Shanghai) Co., Ltd. from 2018 to 2019, where she was the lead physician in charge of multiple global and regional oncology and haematology studies.

From January 2007 to January 2018, Dr. Shi worked as a medical director at the Singapore and China offices of PAREXEL International China Pte. Ltd., where she led the Asia Pacific medical and pharmacovigilance functions and supported drug development for both global and China-pharmaceutical companies.

Dr. Shi obtained a Ph.D. in microbiology from the National University of Singapore in 2006. She obtained her medical doctor degree and a master of science in otolaryngology from Shan Dong Medical University in 1998 and 2001, respectively.

Dr. Yujuan La (喇玉娟), Ph.D., aged 47, joined us in May 2021 and is our senior vice president of Product Development. In her role, she has overall responsibilities for supervising IND applications, overseeing technology transfer and business collaborations, leading chemistry, manufacturing, and controls (CMC) development projects covering the entire life cycle of product development, including upstream and downstream process development, analytical method development and validation, manufacturing scaling-up, clinical sample production and quality assurance management.

Dr. La has 19 years of extensive experience in the biopharmaceutical field, specializing in the research and development, production, quality management, and project management of therapeutic antibody drugs. She successfully advanced multiple IND applications, technology transfers and business collaborations and led various CMC development projects. Prior to joining us, Dr. La worked at Startup Biotech Co., Ltd. as an executive director of preclinical development from September 2020 to April 2021, where she was mainly responsible for handling bispecific antibody drug related research and development, CMC project management and formulating portfolio strategy. Dr. La worked at CRO/CDMO Biopharm Co., Ltd. from October 2018 to August 2020 and her last position held was the vice president and senior director. She was mainly responsible for leading CMC projects (including maintaining service delivery), providing business development and sales support, and planning on marketing and resources strategies. From June 2008 to October 2018, Dr. La worked at Biopharmaceutical Co., Ltd. and she served successively as the Senior Director of Process Development and Quality Assurance Management. She was responsible for (i) establishing the process development team and platform, including product process development and manufacturing, process optimization and scale-up; (ii) building the quality system; and (iii) establishing a continuous improvement quality assurance system to ensure that the quality of drugs from research and development to clinical trials meets the corresponding quality specification. From June 2006 to May 2008, Dr. La was a research associate at Bio-X Centre of Shanghai Jiaotong University, where she was responsible for research and teaching.

Dr. La obtained a Ph.D. in biochemistry and molecular biology from Shanghai Jiao Tong University in 2006. She obtained her bachelor's degree in biology from Inner Mongolia University in 2000.

Ms. Weicong Ni (倪維聰), aged 34, joined us in August 2018 and currently serves as Chief Financial Officer and one of our joint company secretaries. In her role, she has overall responsibilities for financial management and control, corporate finance, investor relations and board related matters. Prior to her current roles, Ms. Ni served various roles within the Company including head of capital markets and chief of staff to CEO, reporting directly to our chief executive officer. Ms. Ni also acts as a director in one of our subsidiaries.

Ms. Ni has more than 10 years of experience in capital markets and corporate financial management with exposure in both sell side and buy side in public and private markets. Prior to joining us, from July 2013 to May 2016, Ms. Ni worked at Deutsche Bank Hong Kong branch as an investment banker advising public and private companies in Asia on equity and debt financing, investments, and merger and acquisition, across a few industries from healthcare to internet and technology. Ms. Ni also gained experience as a public market investor in the United States in 2017.

Ms. Ni received her bachelor's degree in finance and economics from Hong Kong University of Science and Technology in 2013 and an MBA degree from Harvard Business School in 2018. Ms. Ni is a Chartered Financial Analyst.

Ms. Yinghua Zhang (張英華), aged 46, joined us in August 2016. She currently is our senior vice president and head of operations. In her role, she oversees the development and implementation of our talent management and strategic workforce planning. She also provides oversight for legal & compliance, government and administration affairs, and the project management office. Upon joining CStone, she worked as the role of HR and Administration Lead, establishing this department from the ground up and progressively extending her management responsibilities to encompass more enabling functions. Ms. Zhang also acts as a director in certain of our subsidiaries.

Ms. Zhang has more than 20 years' working experience in the life science industry. Prior to joining us, Ms. Zhang was the HR lead at Simcere-MSD (Shanghai) Pharmaceuticals Co., Ltd. She was actively involved in the initial planning and establishment of a joint venture company, and she was responsible for orchestrating the foundational organizational framework and overseeing personnel recruitment during the nascent stages of the company's inception. From December 2002 to August 2011, Ms. Zhang worked at the various subsidiaries of Simcere Pharmaceutical (a company listed on the Stock Exchange (stock code: 2096)) and her last position was the HR head of the Shanghai subsidiary. From July 2000 to November 2002, she was the administration assistant at Jiangsu Scottwilson Engineering Consulting Co., Ltd.

Ms. Zhang obtained her master's degree in applied psychology from Nankai University and bachelor's degree in business management from Inner Mongolia University of Finance and Economics.

Other than the working relationships in the Company, there was no other relationship between any of the Directors or senior management of the Company in respect of finance, business and family or in other material aspects.

Other Information

CHANGES IN INFORMATION OF DIRECTORS

Pursuant to Rule 13.51B(1) of the Listing Rules, the changes in Directors' information after publication of the 2024 annual report of the Company are set out below:

- Mr. Xianghong Lin retired as a non-executive Director with effect from June 25, 2025;
- Dr. Paul Herbert Chew retired as an independent non-executive Director, a member of the Audit Committee, the Compensation Committee, the Nomination Committee and the Strategy Committee with effect from June 25, 2025;
- Mr. Hongbin Sun resigned as an independent non-executive Director, the chairman of the Audit Committee, a member of the Nomination Committee and the Investment Committee with effect from June 25, 2025;
- Ms. Yip Betty Ho was appointed as the chairperson of the Audit Committee, a member of the Compensation Committee, the Nomination Committee, the Strategy Committee and the Investment Committee with effect from June 25, 2025; and
- Mr. Kenneth Howard Jarrett was appointed as an independent non-executive Director and a member of the Audit Committee and the Strategy Committee with effect from September 23, 2025.

Save as disclosed above and in this interim report, there has been no other change of information of Directors pursuant to Rule 13.51B(1) of the Listing Rules.

COMPLIANCE WITH THE CORPORATE GOVERNANCE CODE

The Board is committed to achieving high corporate governance standards. During the Reporting Period, the Company has complied with all the code provisions as set out in Part 2 of the CG Code contained in Appendix C1 to the Listing Rules.

We will continue to regularly review and monitor its corporate governance practices to ensure compliance with the CG Code, and maintain a high standard of corporate governance practices of the Company.

MODEL CODE FOR SECURITIES TRANSACTIONS BY DIRECTORS OF LISTED ISSUERS

We have adopted our own code of conduct, the Securities Transactions Code, which applies to all Directors on terms not less exacting than the required standard indicated by the Model Code as set out in Appendix C3 to the Listing Rules.

Specific enquiries have been made to all the Directors and they have confirmed that they have complied with the Securities Transactions Code during the Reporting Period. The Company's employees, who are likely to be in possession of our unpublished inside information, are subject to the Model Code. No incident of non-compliance of the Model Code by the employees was noted by the Company as of the date of this interim report.

RE-COMPLIANCE WITH RULES 3.10(1) AND 3.21 OF THE LISTING RULES

Following the retirement of Dr. Paul Herbert Chew and the resignation of Mr. Hongbin Sun on June 25, 2025, the number of independent non-executive directors on the Board decreased to two independent non-executive Directors. As such, the Company is unable to meet the following requirements under the Listing Rules: (i) the requirement that the Board shall comprise a minimum of three independent non-executive directors under Rule 3.10(1) of the Listing Rules; and (ii) the requirement that the Audit Committee shall comprise a minimum of three members under Rule 3.21 of the Listing Rules. Following the appointment of Mr. Kenneth Howard Jarrett on September 23, 2025, the Company has re-complied with Rules 3.10(1) and 3.21 of the Listing Rules.

PURCHASE, SALE OR REDEMPTION OF LISTED SECURITIES

Neither the Company nor any of its subsidiaries purchased, sold or redeemed any of the Company's listed securities (including any sale of treasury Shares (as defined under the Listing Rules)) during the Reporting Period. As at June 30, 2025, the Company did not hold any treasury Shares (as defined under the Listing Rules).

MATERIAL LITIGATION

The Company was not involved in any material litigation or arbitration during the Reporting Period. The Directors are also not aware of any material litigation or claims that were pending or threatened against the Group during the Reporting Period.

CONTINUING DISCLOSURE OBLIGATIONS PURSUANT TO THE LISTING RULES

Save as disclosed in this interim report, the Company does not have any other disclosure obligations under Rules 13.20, 13.21 and 13.22 of the Listing Rules.

MATERIAL EVENTS AFTER THE REPORTING PERIOD

On July 16, 2025, the Company completed the placing of 100,000,000 placing shares by a placing agent to not less than six placees at the placing price of HK$4.72 per placing share, representing 6.83% of the issued share capital of the Company as enlarged by the allotment and issue of the placing shares immediately upon completion of the placing. The Company received net proceeds from the placing, after deducting the placing commission and other related expenses and professional fees, of approximately HK$467.28 million. Please refer to the announcements of the Company dated July 9, 2025 and July 16, 2025 for more details.

Save as disclosed above, the Group has no other material events after the Reporting Period and up to the date of this interim report.

USE OF NET PROCEEDS

On September 30, 2020 (before trading hours), the Company entered into the share subscription agreement with Pfizer, pursuant to which Pfizer has conditionally agreed to subscribe for an aggregate of 115,928,803 subscription shares (being ordinary shares of the Company) at the subscription price of approximately HK$13.37 per Share (the closing price of the Company as quoted on the Stock Exchange on September 29, 2020 was HK$9.30 per Share) (the "**Share Subscription**"). Pfizer applies science and its global resources to improve health and well-being at every stage of life, and was a third party independent of the Company or any of its connected person at the time of the Share Subscription. The gross proceeds from the allotment and issue of the subscription shares were approximately US$200.0 million (equivalent to approximately RMB1,355.9 million), which will be used for the funding of the development activities under the collaboration agreement dated September 30, 2020 (the "**Collaboration Agreement**"). The Company entered into the Share Subscription and the Collaboration Agreement to advance the Company's strategic, commercial and financial objectives as it transitions into a fully integrated biopharma company. All the conditions of the subscription have been fulfilled and the closing of the subscription took place on October 9, 2020. The use of these proceeds is in line with the planned use and there is no significant change.

The table below sets out the planned applications of the proceeds and actual usage up to June 30, 2025:

	% of use of proceeds	Proceeds from the subscription *(RMB million)*	Unutilized net proceeds as of December 31, 2024 *(RMB million)*	Actual usage during the Reporting Period *(RMB million)*	Unutilized net proceeds as of June 30, 2025 *(RMB million)*
Fund the development activities under the collaboration agreement	100%	1,355.9	409.3	40.6	368.7

Note: The unutilized net proceeds are planned to be put into use by December 31, 2025. Please refer to the 2023 annual report of the Company for details.

On April 2, 2025 (before trading hours), the Company entered into a placing agreement with Morgan Stanley Asia Limited (the "**Placing Agent**"), pursuant to which the Company agreed to place, through the Placing Agent, an aggregate of 80,000,000 placing shares (being ordinary shares of the Company) to not less than six placees at a price of HK$2.933 per placing share (the closing price of the Company as quoted on the Stock Exchange on April 1, 2025 was HK$3.45 per Share). The net placing price (after deducting related costs and expenses to be borne by the Company) is approximately HK$2.904 per Share. The aggregate nominal value of the placing shares under the placing is US$8,000. The placees are professional, institutional or other investors, and together with their ultimate beneficial owners, are third parties independent of the Company and any of its connected persons. The placing would enlarge the Shareholder base and the capital base of the Company, and strengthen the Group's financial position for its future development. The net proceeds from the placing, after deducting the placing commission and other related expenses and professional fees, were approximately HK$232.29 million (equivalent to approximately RMB215.82 million). The Company intends to use the net proceeds for purposes as stated below. All the conditions of the placing were fulfilled and the closing of the placing took place on April 10, 2025. The use of these proceeds is in line with the planned use and there is no significant change or delay.

The table below sets out the planned applications of the proceeds and actual usage up to June 30, 2025:

	% of use of proceeds	Proceeds from the placing *(RMB million)*	Actual usage during the Reporting Period *(RMB million)*	Unutilized net proceeds as of June 30, 2025 *(RMB million)*
Research and development of Pipeline "2.0", including in particular CS5001, a clinical stage ROR1 ADC (a potentially best-in-class ROR1 ADC), and CS2009, a trispecific antibody targeting PD-1, VEGFA and CTLA-4 (a potentially first-in-class/ best-in-class next-generation immuno-oncology backbone)	90%	194.24	25.97	168.27
General corporate purposes	10%	21.58	4.28	17.30
Total	100%	215.82	30.25	185.57

Note: The unutilized net proceeds are planned to be put into use by December 31, 2026.

AUDIT COMMITTEE

The Company has established the Audit Committee with written terms of reference in accordance with the Listing Rules. The Audit Committee currently comprises three independent non-executive Directors, namely, Ms. Yip Betty Ho (Chairperson), Mr. Ting Yuk Anthony Wu and Mr. Kenneth Howard Jarrett.

The Audit Committee has considered and reviewed the accounting principles and practices adopted by the Group and discussed matters in relation to internal control and financial reporting with the management. The Audit Committee reviewed and considered that the interim financial results for the six months ended June 30, 2025 are in compliance with the relevant accounting standards, rules and regulations and appropriate disclosures have been duly made.

REVIEW OF INTERIM RESULTS

The independent auditors of the Company, namely Deloitte Touche Tohmatsu, have conducted a review of the interim financial information in accordance with the International Standard on Review Engagement 2410 *Review of Interim Financial Information Performed by the Independent Auditor of the Entity* issued by the International Auditing and Assurance Standards Board. The Audit Committee has jointly reviewed with the management of the Company, the accounting principles and policies adopted by the Company and discussed internal control and financial reporting matters (including the review of the unaudited interim results for the six months ended June 30, 2025) of the Group.

INTERIM DIVIDEND

The Board does not recommend the payment of an interim dividend for the six months ended June 30, 2025 (2024: Nil).

DIRECTORS' AND CHIEF EXECUTIVES' INTERESTS IN SHARES AND UNDERLYING SHARES OF THE COMPANY AND ITS ASSOCIATED CORPORATIONS

Interests and Short Positions of our Directors in the Share Capital of the Company

As of June 30, 2025, the interests and short positions of the Directors and the chief executive of the Company in the Shares, underlying Shares or debentures of the Company or any of the associated corporations of the Company (within the meaning of Part XV of the SFO), which were required (a) to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which they were taken or deemed to have under such provisions of the SFO); or (b) pursuant to section 352 of the SFO, to be entered in the register referred to therein; or (c) to be notified to the Company and the Stock Exchange pursuant to the Model Code, are as follows:

Long Position in the Shares of the Company

Name of Director or chief executive	Nature of interest	Number and class of securities	Approximate percentage of interest in our Company[1]
Dr. Jianxin Yang, CEO and executive Director	Beneficial Owner	74,146,256 Shares[2]	5.43%
Mr. Kenneth Walton Hitchner III, non-executive Director	Beneficial Owner	2,613,481 Shares[3]	0.19%
Dr. Wei Li, Chairman of Board and non-executive Director	Beneficial Owner	2,000,000 Shares[4]	0.15%
Mr. Edward Hu, non-executive Director	Beneficial Owner	2,921,000 Shares[5]	0.21%

Notes:

(1) The calculation is based on the total number of 1,364,501,335 Shares in issue as of June 30, 2025.

(2) Includes (i) 17,758,131 Shares beneficially held by Dr. Jianxin Yang; (ii) Dr. Yang's entitlement to receive up to 3,000,000 Shares pursuant to the exercise of options granted to him under the Pre-IPO Incentivization Plan, subject to the vesting and other conditions of those options; (iii) share options to subscribe for 50,876,000 Shares granted to him under the Post-IPO ESOP, subject to the vesting and other conditions of those options; and (iv) Dr. Yang's entitlement to restricted share units equivalent to 2,512,125 Shares granted to him under the Post-IPO RSU Scheme, subject to vesting conditions.

(3) Includes (i) 2,597,485 Shares beneficially held by Mr. Kenneth Walton Hitchner III; and (ii) Mr. Kenneth Walton Hitchner III's entitlement to restricted share units equivalent to 15,996 Shares granted to him under the Post-IPO RSU Scheme, subject to vesting conditions.

(4) Includes (i) 291,666 Shares beneficially held by Dr. Wei Li; (ii) Dr. Wei Li's entitlement to restricted share units equivalent to 708,334 Shares granted to him under the Post-IPO RSU Scheme, subject to vesting conditions; and (iii) share options to subscribe for 1,000,000 Shares granted to him under the Post-IPO ESOP, subject to the vesting conditions.

(5) Includes (i) 1,212,666 Shares beneficially held by Mr. Edward Hu; (ii) Mr. Edward Hu's entitlement to restricted share units equivalent to 708,334 Shares granted to him under the Post-IPO RSU Scheme, subject to vesting conditions; and (iii) share options to subscribe for 1,000,000 Shares granted to him under the Post-IPO ESOP, subject to the vesting conditions.

Save as disclosed above and to the best knowledge of the Directors, none of the Directors or the chief executive of the Company has or is deemed to have any interests or short positions in the Shares, underlying Shares or debentures of the Company or any of its associated corporations as of June 30, 2025.

SUBSTANTIAL SHAREHOLDERS' INTERESTS IN SHARES AND UNDERLYING SHARES OF THE COMPANY

Interests and Short Positions Discloseable under Divisions 2 and 3 of Part XV of the SFO

As of June 30, 2025, the following are the persons, other than the Directors or the chief executive of the Company, who had interests or short positions in the Shares and underlying Shares as recorded in the register of interests required to be kept by the Company pursuant to Section 336 of Part XV of the SFO:

Long Position in the Shares of the Company

Substantial Shareholder	Capacity/Nature of Interest	Total number of Shares/underlying Shares	Approximately percentage of interest in our Company[1]
WuXi Healthcare Ventures II, L.P.[2]	Beneficial interest	293,381,444	21.50%
WuXi Healthcare Management, LLC[2]	Interest in controlled corporation	293,381,444	21.50%
Pfizer Corporation Hong Kong Limited[3]	Beneficial interest	115,928,803	8.50%
Pfizer Inc.[3]	Interest in controlled corporation	115,928,803	8.50%

Notes:

(1) The calculation is based on the total number of 1,364,501,335 Shares in issue as of June 30, 2025.

(2) As of June 30, 2025, WuXi Healthcare Ventures II, L.P. directly held 293,381,444 Shares. To the best knowledge of us, WuXi Healthcare Ventures II, L.P. is a limited partnership established under the laws of Cayman Islands managed by its sole general partner, WuXi Healthcare Management, LLC, a Cayman Islands exempted company in which each of its five members holds an equal share of equity interest. For the purpose of the SFO, WuXi Healthcare Management, LLC is deemed to have an interest in the Shares held by WuXi Healthcare Ventures II, L.P.

(3) As of June 30, 2025, Pfizer Corporation Hong Kong Limited, a company incorporated in Hong Kong with limited liability, directly held 115,928,803 Shares. For the purpose of the SFO, Pfizer Inc., a Delaware-incorporated company listed on the New York Stock Exchange and indirectly holding 100% of the shares in Pfizer Corporation Hong Kong Limited is deemed to have an interest in the Shares held by Pfizer Corporation Hong Kong Limited.

Save as disclosed above and to the best knowledge of the Directors, as of June 30, 2025, the Company is not aware of any other person (other than the Directors or the chief executive of the Company) who had an interest or short position in the Shares or underlying Shares as recorded in the register required to be kept by the Company pursuant to Section 336 of the SFO.

SHARE INCENTIVIZATION SCHEMES

We have adopted three share incentivization schemes, collectively referred to as the Share Incentivization Schemes.

Pre-IPO Incentivization Plan

We have adopted the Pre-IPO Incentivization Plan by the resolutions in writing of the Board passed on July 7, 2017 and as amended and restated on August 14, 2018 and as further amended and restated on January 26, 2019 and as further amended and restated on January 7, 2020. No options and RSUs will be granted under the Pre-IPO Incentivization Plan after completion of the Listing.

During the Reporting Period, pursuant to the Pre-IPO Incentivization Plan, no options or RSUs were granted to Directors, other related entity participants, other service providers or other employee participants of the Group. As of June 30, 2025, no further options or RSUs were available for grant under the Pre-IPO Incentivization Plan. All options granted to Directors and other employee participants of the Group under the Pre-IPO Incentivization Plan will continue to remain valid and exercisable in accordance with the terms of the Pre-IPO Incentivization Plan. All RSUs granted to Directors and other employee participants of the Group under the Pre-IPO Incentivization Plan had been fully vested.

Movement of the options, which were granted under the Pre-IPO Incentivization Plan, during the Reporting Period is as follows:

Name of Participant or Category of Participant	Date of grant	Number of options held at January 1, 2025	Number of options granted	Number of options lapsed	Number of options cancelled	Number of options exercised	Number of options held at June 30, 2025	Exercise Price	Exercise Period[1]	Vesting Period[2]	Weighted average closing price of the shares immediately before the dates on which the options were exercised	Fair value of options at the date of grant
Director												
Dr. Jianxin Yang, CEO and executive Director	2016-12-07	3,000,000	–	–	–	–	3,000,000	HKD0.20–HKD0.39	10 years	4 years	–	US$0.33–US$0.35
Other employee participants	2016-7-11-2019-2-25	1,702,487	–	172	–	143,356	1,558,959	HKD0.20–HKD4.65	10 years	4 years	HKD2.30	US$0.24–US$1.39
Other related entity participants						N/A						
Other service providers						N/A						
Total		4,702,487	–	172	–	143,356	4,558,959					

Notes:

(1) The exercise period of all options in the table above shall be 10 years from the date of grant.

(2) The vesting schedule of all options in the table above shall be 25% of the shares will be vested on the first anniversary of the vesting commencement date, and the remaining shares will be vested with equal monthly installments over the following thirty-six months.

(3) The closing price of the Shares immediately before the dates on which the options were granted was not applicable as the Company was not yet listed on the dates of grant.

(4) Given no option has been granted and no more options will be granted under the Pre-IPO Incentivization Plan, it is not applicable for the Company to set out the number of Shares that may be issued in respect of the options granted under the Pre-IPO Incentivization Plan during the Reporting Period divided by the weighted average number of Shares in issue (excluding treasury Shares).

Post-IPO ESOP

We have adopted the Post-IPO ESOP by resolutions passed by our Company on January 30, 2019, with effect upon completion of the Listing, and as amended and restated on March 7, 2023.

The total number of options available for grant under the Post-IPO ESOP as of January 1, 2025 and June 30, 2025 was 73,262,106 and 51,518,706, respectively. The total number of options available for grant under the Service Provider Sublimit of the Post-IPO ESOP as of January 1, 2025 and June 30, 2025 was 12,663,640 and 12,663,640, respectively. As at the date of this report, the total number of shares available for issue under the Post-IPO ESOP is 83,472,855, representing approximately 5.66% of the Shares in issue (excluding treasury Shares).

The grant of options under the Post-IPO ESOP to Dr. Jianxin Yang (the "**Grantee**") on April 11, 2025 are not subject to performance targets. Having considered that (i) the grant of options could bring about an immediate incentivization effect for the Grantee, which was considered a more attractive motivation to the Grantee for continuing to serve in such roles; (ii) the grant of options to the Grantee served as a recognition of his past contributions to the Group; and (iii) the grant of options without performance target was consistent with the Company's customary practice on previous grants of share incentives to the Directors, employees of the Company (including members of senior management) and service providers, the Compensation Committee considered that without performance targets, the grant of options to the Grantee could align the interests of the Grantee with incentive to the Grantee to work towards the continued success of the Group, and reinforce his commitment to provide long-term services to the Group, which is in line with the purpose of the Post-IPO ESOP.

Movement of the options, which were granted under the Post-IPO ESOP, during the Reporting Period is as follows:

Name of Participant or Category of Participant	Date of grant	Closing price of shares immediately before the date on which the options were granted	Number of options held at January 1, 2025	Number of options granted	Number of options lapsed	Number of options cancelled	Number of options exercised	Number of options held at June 30, 2025	Exercise Price	Exercise Period[1]	Vesting Period	Weighted average closing price of the shares immediately before the dates on which the options were exercised	Fair value of options at the date of grant
Directors													
Dr. Jianxin Yang, CEO and executive Director	2022-08-30	HKD4.77	28,000,000	–	–	–	–	28,000,000	HKD4.660	10 years	4 years[4]	–	HKD1.28 – HKD3.12
	2023-01-06	HKD4.92	4,340,000	–	–	–	–	4,340,000	HKD4.900	10 years	4 years[5]	–	HKD3.26
	2023-11-08	HKD2.28	14,000,000	–	–	–	–	14,000,000	HKD2.350	10 years	4 years[6]	–	HKD1.11 – HKD1.16
	2024-03-28	HKD0.96	1,890,000	–	–	–	–	1,890,000	HKD0.944	10 years	4 years[9]	–	HKD0.67
	2025-04-11	HKD2.31	–	2,646,000	–	–	–	2,646,000	HKD2.406	10 years	4 years[13]	–	HKD1.53
Dr. Wei Li, Chairman and non-executive Director	2024-03-28	HKD0.96	1,000,000	–	–	–	–	1,000,000	HKD0.944	10 years	4 years[9]	–	HKD0.58
Mr. Edward Hu, non-executive Director	2024-03-28	HKD0.96	1,000,000	–	–	–	–	1,000,000	HKD0.944	10 years	4 years[9]	–	HKD0.58
Other employee participants	2019-04-01	HKD15.88	7,511	–	–	–	–	7,511	HKD15.860	10 years	4 years[3]	–	HKD7.19
	2019-10-11	HKD12.04	8,000	–	–	–	–	8,000	HKD12.200	10 years	4 years[3]	–	HKD6.90 – HKD7.02
	2020-04-01	HKD8.70	618,690	–	343,749	–	–	274,941	HKD8.850	10 years	4 years[3]	–	HKD4.58 – HKD4.68
	2020-11-30	HKD9.99	1,618	–	–	–	–	1,618	HKD9.960	10 years	4 years[3]	–	HKD4.83 – HKD5.02
	2021-04-01	HKD9.25	1,362,649	–	1,102,096	–	–	260,553	HKD9.850	10 years	4 years[3]	–	HKD5.26 – HKD6.32
	2021-12-10	HKD9.75	22,500	–	–	–	–	22,500	HKD9.588	10 years	4 years[3]	–	HKD4.77 – HKD5.15
	2022-06-06	HKD5.10	3,059,502	–	1,461,005	–	–	1,598,497	HKD5.274	10 years	4 years[3]	–	HKD2.63 – HKD2.93

Name of Participant or Category of Participant	Date of grant	Closing price of shares immediately before the date on which the options were granted	Number of options held at January 1, 2025	Number of options granted	Number of options lapsed	Number of options cancelled	Number of options exercised	Number of options held at June 30, 2025	Exercise Price	Exercise Period[1]	Vesting Period	Weighted average closing price of the shares immediately before the dates on which the options were exercised	Fair value of options at the date of grant
	2022-07-21	HKD4.90	2,209,500	–	451,005	–	–	1,758,495	HKD5.002	10 years	4 years[3]	–	HKD2.30 – HKD2.39
	2023-01-06	HKD4.92	4,189,374	–	87,974	–	–	4,101,400	HKD4.900	10 years	4 years[3]	–	HKD2.63 – HKD2.83
	2023-03-23	HKD3.67	7,827,571	–	647,267	–	–	7,180,304	HKD3.768	10 years	4 years[8]	–	HKD0.75 – HKD2.01
	2024-03-28	HKD0.96	6,620,400	–	61,458	–	88,625	6,470,317	HKD0.944	10 years	4 years[9]	HKD4.45	HKD0.45 – HKD0.48
	2024-10-18	HKD1.62	6,280,000	–	–	–	–	6,280,000	HKD1.760	10 years	4 years [10][11][12]	–	HKD0.86 – HKD1.04
	2025-04-11	HKD2.31	–	13,120,800	–	–	–	13,120,800	HKD2.406	10 years	4 years[13]	–	HKD1.15 – HKD1.27
Other related entity participants							N/A						
Other service providers[7]	2023-03-23	HKD3.67	59,840	–	–	–	18,600	41,240	HKD3.768	10 years	4 years[8]	HKD4.69	HKD1.86
	2024-03-28	HKD0.96	50,000	–	–	–	13,542	36,458	HKD0.944	10 years	4 years[9]	HKD3.40	HKD0.55
Total			82,547,155	15,766,800	4,154,554	–	120,767	94,038,634					

Notes:

(1) The exercise period of all options in the table above shall be 10 years from the date of grant.

(2) All options granted are subject to any of the individual performance result and other requirements as set out in the grant letters to be entered into between each of the grantees and the Company.

(3) The vesting schedules of the grant of options shall vest in accordance with either of the followings:

- 25% of shall vest on the first anniversary of the date of grant and the remaining shares shall vest with equal monthly installments over the thirty-six months immediately following the first anniversary of the date of grant;
- 25% shall vest on each of the first to fourth anniversary of the date of grant; or
- 25% shall vest on each of the first to fourth anniversary of the date of satisfaction of the respective performance target milestone.

(4) The vesting schedules of the grant of 28,000,000 options to Dr. Jianxin Yang shall be as follows:

- 14,000,000 options granted to Dr. Yang shall vest as follows:

  25% shall vest on the first anniversary of August 25, 2022 (rounding to the nearest whole option);

  25% shall vest on the second anniversary of August 25, 2022 (rounding to the nearest whole option);

  25% shall vest on the third anniversary of August 25, 2022 (rounding to the nearest whole option); and

  25% shall vest on the fourth anniversary of August 25, 2022 (rounding to the nearest whole option).

- The remaining 14,000,000 options granted to Dr. Yang are divided into various batches of options. Upon satisfaction of the performance target milestone specified for each batch of options, the respective batch of options shall vest as follows:

  25% shall vest on the first anniversary of the date of satisfaction of the respective performance target milestone (rounding to the nearest whole option);

  25% shall vest on the second anniversary of the date of satisfaction of the respective performance target milestone (rounding to the nearest whole option);

  25% shall vest on the third anniversary of the date of satisfaction of the respective performance target milestone (rounding to the nearest whole option); and

  25% shall vest on the fourth anniversary of the date of satisfaction of the respective performance target milestone (rounding to the nearest whole option).

(5) The vesting schedules of the grant of 4,340,000 options to Dr. Jianxin Yang shall be as follows:

- 25% shall vest on the first anniversary of the date of grant (rounding to the nearest whole option); and

- 75% shall vest monthly in equal installments over the 36 months (rounding to the nearest whole option) immediately following the first anniversary of the date of grant.

(6) The vesting schedules of the grant of 14,000,000 Options to Dr. Jianxin Yang shall be as follows:

Upon satisfaction of the performance target milestone specified for each batch of Options, the respective batch of Options shall vest as follows:

- 25% of Share Options corresponding to the relevant performance target milestone shall vest on the first anniversary of the respective the date of satisfaction of the respective performance target milestone; and

- the remaining 75% of Share Options corresponding to the relevant performance target milestone shall vest monthly in equal installments over the 36 months immediately following the first anniversary of the date of satisfaction of the respective performance target milestone.

(7) According to the relevant scheme rules, Service Providers means any persons (nature person or corporate entity) who provide services to the Group on a continuing and recurring basis in the ordinary course of business of the Group which are in the interests of the long term growth of the Group, including independent contractor, consultant and/or advisors for the research & development, product commercialization, marketing, innovation upgrading, strategic/commercial planning on corporate image and investor relations in investment environment of the Company (excluding any placing agents or financial advisers providing advisory services for fundraising, mergers or acquisition, and service providers such as auditors or valuers who provide assurance, or are required to perform their services with impartiality and objectivity).

(8) The vesting commencement date of the 12,721,120 options out of the total of 14,321,120 options granted to other employee participants and service providers on March 23, 2023 (the "**March 2023 Grant**") was April 1, 2023 (the "**Vesting Commencement Date**"). No performance targets were attached to the 12,721,120 options granted. The 12,721,120 options shall commence vesting as follows:

480,000 options granted under the March 2023 Grant shall vest as follows:

- 25% shall vest on the first anniversary of the Vesting Commencement Date (rounding to the nearest whole option);
- 25% shall vest on the second anniversary of the Vesting Commencement Date (rounding to the nearest whole option);
- 25% shall vest on the third anniversary of the Vesting Commencement Date (rounding to the nearest whole option); and
- 25% shall vest on the fourth anniversary of the Vesting Commencement Date (rounding to the nearest whole option).

12,241,120 options granted under the March 2023 Grant shall vest as follows:

- 25% shall vest on the first anniversary of the Vesting Commencement Date (rounding to the nearest whole option); and
- 75% shall vest monthly in equal installments over the 36 months (rounding to the nearest whole option) immediately following the first anniversary of the Vesting Commencement Date.

The remaining 1,600,000 options out of the March 2023 Grant shall commence vesting upon satisfaction of the performance target milestone (including individual performance based on periodic performance assessment and annual review results by the Company) as follows:

- 25% shall vest on the first anniversary of the date of satisfaction of the respective performance target milestone (rounding to the nearest whole option);
- 25% shall vest on the second anniversary of the date of satisfaction of the respective performance target milestone (rounding to the nearest whole option);
- 25% shall vest on the third anniversary of the date of satisfaction of the respective performance target milestone (rounding to the nearest whole option); and
- 25% shall vest on the fourth anniversary of the date of satisfaction of the respective performance target milestone (rounding to the nearest whole option).

(9) The vesting commencement date of the total of 11,202,900 options granted to Directors, other employee participants and other service providers on March 28, 2024 was April 1, 2024 (the "**Vesting Commencement Date**"). The grant of such options is not subject to performance targets and shall vest as follows:

- 25% shall vest on the first anniversary the Vesting Commencement Date (rounding to the nearest whole option); and
- 75% shall vest monthly in equal installments over the 36 months (rounding to the nearest whole option) immediately following the first anniversary of the Vesting Commencement Date.

The grant of options under the Post-IPO ESOP to Dr. Jianxin Yang, Dr. Wei Li and Mr. Edward Hu (the "**Directors Options Grantees**") on March 28, 2024 are not subject to performance targets. Having considered that (i) the grant of options could bring about an immediate incentivization effect for the Directors Options Grantees, which was considered a more attractive motivation to the Directors Options Grantees for continuing to serve in such roles; (ii) the grant of options to the Directors Options Grantees served as a recognition of their past contributions to the Group; and (iii) the grant of options without performance target was consistent with the Company's customary practice on previous grants of share incentives to the Directors, employees of the Company (including members of senior management) and service providers, the Compensation Committee considered that without performance targets, the grant of options to the Directors Options Grantees could align the interests of the Directors Options Grantees with incentive to the Directors Options Grantees to work towards the continued success of the Group, and reinforce their commitment to provide long-term services to the Group, which is in line with the purpose of the Post-IPO ESOP.

(10) The vesting commencement date of the 2,000,000 options granted to a member of the senior management shall commence on October 18, 2024 (the "**Senior Manager Options Vesting Commencement Date**") and shall vest as follow:

- 25% shall vest on the first anniversary of the Senior Manager Options Vesting Commencement Date (rounding to the nearest whole option); and
- 75% shall vest monthly in equal instalments over the 36 months (rounding to the nearest whole option) immediately following the first anniversary of the Senior Manager Options Vesting Commencement Date.

The grant of 2,000,000 options under the Post-IPO ESOP to a member of the senior management on October 18, 2024 are not subject to performance targets. Having considered that (i) the grant of options to a member of the senior management served as a recognition of his/her past contributions to the Group; (ii) the grant of options can bring about an immediate incentivization effect of the grantee, which was considered a more attractive motivation to the grantee; and (iii) the grant of options without performance target was consistent with the Company's customary practice on previous grants of share incentives to the Directors, employees of the Company (including members of senior management) and service providers, the Compensation Committee considered that without any performance targets, the grant of the 2,000,000 options to a member of the senior management could align the interests of the relevant grantee with incentive to the relevant grantee to work towards the continued success of the Group, and reinforce his/her commitment in providing long-term services to the Group, which is in line with the purpose of the Post-IPO ESOP.

(11) Among the aggregate of 6,280,000 options granted to the grantees, the vesting period of the 4,000,000 options granted shall commence on the dates upon which the relevant employee participant having fulfilled the following performance target milestones (the "**Milestone Vesting Commencement Dates**"):

- Vesting period of 1,000,000 options shall commence on the date of fulfilment of the first performance target milestone;
- Vesting period of 2,500,000 options shall commence on the date of fulfilment of the second performance target milestone; and
- Vesting period of 500,000 options shall commence on the date of fulfilment of the third performance target milestone.

Subject to fulfilment of the respective performance target milestones, 4,000,000 options granted shall vest as follows:

- 25% of options corresponding to the relevant performance target milestone shall vest on the first anniversary of the respective Milestone Vesting Commencement Dates;
- 25% of options corresponding to the relevant performance target milestone shall vest on the second anniversary of the respective Milestone Vesting Commencement Dates;
- 25% of options corresponding to the relevant performance target milestone shall vest on the third anniversary of the respective Milestone Vesting Commencement Dates; and
- 25% of options corresponding to the relevant performance target milestone shall vest on the fourth anniversary of the respective Milestone Vesting Commencement Dates.

(12) Among the 280,000 options granted to the employee participants, the vesting period of 80,000 options shall commence on June 13, 2024 and the vesting period of 200,000 options shall commence on October 9, 2024 (the "**Employee Options Vesting Commencement Dates**"). The 280,000 options shall vest as follows:

- 25% shall vest on the first anniversary of the respective Employee Options Vesting Commencement Dates (rounding to the nearest whole option);
- 25% shall vest on the second anniversary of the respective Employee Options Vesting Commencement Dates (rounding to the nearest whole option);
- 25% shall vest on the third anniversary of the respective Employee Options Vesting Commencement Dates (rounding to the nearest whole option); and
- 25% shall vest on the fourth anniversary of the respective Employee Options Vesting Commencement Dates (rounding to the nearest whole option).

The options granted to the grantees shall vest in several batches, with a total vesting period of more than 12 months. Due to administrative reasons, the periods between the date of grant and the first vesting periods for the 280,000 options granted to two of the grantees (none of which is a member of senior management) are less than 12 months to reflect the time from which the options would have been granted as permitted under specific circumstances as set out in the Post-IPO ESOP. In any event, the Board has the discretion to accelerate the above vesting schedules of the options, subject to compliance with the requirements of Rule 17.03F of the Listing Rules as and when appropriate. The Board was of the view that the grant of options and the relevant vesting periods were appropriate and in line with the market practice and the purposes of the Post-IPO ESOP.

(13) The vesting commencement date of the total of 15,766,800 options granted to Dr. Jianxin Yang and other employee participants on April 11, 2025 was April 2, 2025 (the "**Vesting Commencement Date**"). The grant of such options is not subject to performance targets and shall vest as follows:

- 25% shall vest on the first anniversary the Vesting Commencement Date (rounding to the nearest whole option); and
- 75% shall vest monthly in equal installments over the 36 months (rounding to the nearest whole option) immediately following the first anniversary of the Vesting Commencement Date.

The options granted to the grantees will vest in several batches, with a total vesting period of more than 12 months. The period between the date of grant and the first vesting period of the options granted to the grantees are less than 12 months. Having considered, due to administrative reasons and for the purpose of reflecting the time from which the options would have been granted as permitted under specific circumstances as set out in the Post-IPO ESOP, the Board and the Compensation Committee were of the view that the grant of options and the relevant vesting periods are appropriate and in line with market practice and the purposes of the Post-IPO ESOP.

(14) The number of Shares that may be issued in respect of options granted under the Post-IPO ESOP during the Reporting Period divided by the weighted average number of Shares in issue (excluding treasury Shares) for the period was 1.2%.

(15) For details of the basis of measurement for the fair value of options granted, please refer to note 19 to the Condensed Consolidated Financial Statements.

Post-IPO RSU Scheme

We have adopted the Post-IPO RSU Scheme by resolutions passed by our Company on March 22, 2019 and restated and amended by our Company on December 10, 2019, January 7, 2020 and March 7, 2023, as amended from time to time.

The total number of RSUs available for grant under the Post-IPO RSU Scheme as of January 1, 2025 and June 30, 2025 was 73,262,106 and 51,518,706, respectively. The total number of RSUs available for grant under the Service Provider Sublimit of the Post-IPO RSU Scheme as of January 1, 2025 and June 30, 2025 was 12,663,640 and 12,663,640, respectively. As at the date of this report, the total number of shares available for issue under the Post-IPO RSU Scheme was 14,875,047, representing approximately 1.01% of the Shares in issue (excluding treasury Shares).

The grant of options under the Post-IPO RSU Scheme to Dr. Jianxin Yang (the "**Grantee**") on April 11, 2025 are not subject to performance targets. Having considered that (i) the grant of RSUs could bring about an immediate incentivization effect for the Grantee, which was considered a more attractive motivation to the Grantee for continuing to serve in such roles; (ii) the grant of RSUs to the Grantee served as a recognition of his past contributions to the Group; and (iii) the grant of RSUs without performance target was consistent with the Company's customary practice on previous grants of share incentives to the Directors, employees of the Company (including members of senior management) and service providers, the Compensation Committee considered that without performance targets, the grant of RSUs to the Grantee could align the interests of the Grantee with incentive to the Grantee to work towards the continued success of the Group, and reinforce his commitment to provide long-term services to the Group, which is in line with the purpose of the Post-IPO RSU Scheme.

Details of RSUs granted under the Post-IPO RSU Scheme, during the Reporting Period are as follows:

Name of Participant or Category of Participant	Date of grant	Closing price of shares immediately before the date on which the RSUs were granted	Number of RSUs held at January 1, 2025	Number of RSUs granted	Number of RSUs lapsed	Number of RSUs cancelled	Number of RSUs vested	Number of RSUs held at June 30, 2025	Vesting Period	Exercise Period[9]	Purchase Price[8]	Weighted average closing price of the shares immediately before the dates on which the RSUs were vested	Fair value of RSUs at the date of grant
Directors													
Dr. Jianxin Yang, CEO and executive Director	2021-04-01	HKD9.25	100,000	–	–	–	100,000	–	4 years[1]	N/A	Nil	HKD3.11	HKD9.85
	2024-03-28	HKD0.96	1,890,000	–	–	–	511,875	1,378,125	4 years[2]	N/A	Nil	HKD3.15	HKD0.94
	2025-04-11	HKD2.31	–	1,134,000	–	–	–	1,134,000	4 years[7]	N/A	Nil	–	HKD2.39
Dr. Wei Li, Chairman and non-executive Director	2024-03-28	HKD0.96	1,000,000	–	–	–	291,666	708,334	4 years[2]	N/A	Nil	HKD3.15	HKD0.94
Mr. Edward Hu, non-executive Director	2024-03-28	HKD0.96	1,000,000	–	–	–	291,666	708,334	4 years[2]	N/A	Nil	HKD3.15	HKD0.94
Kenneth Walton Hitchner III, non-executive Director	2021-12-10	HKD9.75	15,996	–	–	–	–	15,996	4 years[1]	N/A	Nil	–	HKD9.33
Other employee participants	2019-10-11	HKD12.04	1,151	–	–	–	–	1,151	4 years[1]	N/A	Nil	–	HKD12.20
	2021-04-01	HKD9.25	141,250	–	–	–	140,750	500	4 years[1]	N/A	Nil	HKD3.20	HKD9.85
	2021-07-02	HKD17.10	265,000	–	–	–	225,000	40,000	4 years[1]	N/A	Nil	HKD3.11	HKD16.20
	2021-12-10	HKD9.75	116,056	–	2,000	–	–	114,056	4 years[1]	N/A	Nil	–	HKD9.33
	2023-03-23	HKD3.67	1,279,309	–	10,000	–	224,852	1,044,457	4 years[4][5]	N/A	Nil	HKD2.96	HKD3.57
	2024-03-28	HKD0.96	6,617,400	–	61,875	–	1,896,992	4,658,533	4 years[2]	N/A	Nil	HKD3.19	HKD0.94
	2024-10-18	HKD1.62	200,000	–	–	–	–	200,000	4 years[6]	N/A	Nil	–	HKD1.76
	2025-04-11	HKD2.31	–	5,623,200	–	–	–	5,623,200	4 years[7]	N/A	Nil	–	HKD2.39
Other related entity participants							N/A						
Other service providers[3]	2023-03-23	HKD3.67	11,220	–	–	–	3,740	7,480	4 years[4][5]	N/A	Nil	HKD2.82	HKD3.57
	2024-03-28	HKD0.96	50,000	–	–	–	14,584	35,416	4 years[2]	N/A	Nil	HKD3.10	HKD0.94
Total			12,687,382	6,757,200	73,875	–	3,701,125	15,669,582					

Notes:

(1) The vesting schedules of the grant of RSUs shall vest in accordance with either of the followings:

- 25% of the shares shall vest on the first anniversary of the date of grant and the remaining shares shall vest with equal monthly installments over the thirty-six months immediately following the first anniversary of the date of grant; or
- 25% shall vest on each of the first to fourth anniversary of the date of grant;
- 25% shall vest on each of the first to fourth anniversary of the date of satisfaction of the respective performance target milestone.

(2) The vesting commencement date of the 1,890,000 RSUs granted to Dr. Jianxin Yang, 1,000,000 RSUs granted to Dr. Wei Li and 1,000,000 RSUs granted to Mr. Edward Hu, 7,257,900 RSUs granted to other employee participants and 50,000 RSUs granted to other service providers on March 28, 2024 (the "**March 2024 RSU Grant**") was April 1, 2024 (the "**Vesting Commencement Date**"). No performance targets were attached to the March 2024 RSU Grant. The total of 11,197,900 RSUs granted to Directors, other employee participants and other service providers shall vest as follows:

925,500 RSUs out of the 11,197,900 RSUs granted under the March 2024 RSU Grant shall vest as follows:

- 25% shall vest on the first anniversary of the RSU Vesting Commencement Date (rounding to the nearest whole RSU);
- 25% shall vest on the second anniversary of the RSU Vesting Commencement Date (rounding to the nearest whole RSU);
- 25% shall vest on the third anniversary of the RSU Vesting Commencement Date (rounding to the nearest whole RSU); and
- 25% shall vest on the fourth anniversary of the RSU Vesting Commencement Date (rounding to the nearest whole RSU).

10,272,400 RSUs out of the 11,197,900 RSUs granted under the March 2024 RSU Grant shall vest as follows:

- 25% shall vest on the first anniversary of the RSU Vesting Commencement Date (rounding to the nearest whole RSU); and
- 75% shall vest monthly in equal instalments over the 36 months (rounding to the nearest whole RSU) immediately following the first anniversary of the RSU Vesting Commencement Date.

The grant of RSUs under the Post-IPO RSU Scheme to Dr. Jianxin Yang, Dr. Wei Li and Mr. Edward Hu (the "**Directors RSUs Grantees**") on March 28, 2024 are not subject to performance targets. Having considered that (i) the grant of RSUs could bring about an immediate incentivization effect for the Directors RSUs Grantees, which was considered a more attractive motivation to the Directors RSUs Grantees for continuing to serve in such roles; (ii) the grant of RSUs to the Directors RSUs Grantees served as a recognition of their past contributions to the Group; and (iii) the grant of RSUs without performance target was consistent with the Company's customary practice on previous grants of share incentives to the Directors, employees of the Company (including members of senior management) and service providers, the Compensation Committee considered that without performance targets, the grant of RSUs to the Directors RSUs Grantees could align the interests of the Directors RSUs Grantees with incentive to the Directors RSUs Grantees to work towards the continued success of the Group, and reinforce their commitment to provide long-term services to the Group, which is in line with the purpose of the Post-IPO RSU Scheme.

(3) According to the relevant scheme rules, service providers means any persons (nature person or corporate entity) who provide services to the Group on a continuing and recurring basis in the ordinary course of business of the Group which are in the interests of the long term growth of the Group, including independent contractor, consultant and/or advisors for the research & development, product commercialization, marketing, innovation upgrading, strategic/commercial planning on corporate image and investor relations in investment environment of the Company (excluding any placing agents or financial advisers providing advisory services for fundraising, mergers or acquisition, and service providers such as auditors or valuers who provide assurance, or are required to perform their services with impartiality and objectivity).

(4) The vesting commencement date of the 2,979,180 RSUs out of the total of 3,379,180 RSUs granted to other employee participants and service providers on March 23, 2023 (the "**March 2023 RSU Grant**") was April 1, 2023 (the "**Vesting Commencement Date**"). No performance targets were attached to the 2,979,180 RSUs granted.

The remaining 400,000 RSUs granted under the March 2023 RSU Grant to one employee amongst the other employee participants shall commence vesting upon certain performance target (including individual performance based on periodic performance assessment and annual review results by the Company) and other requirements as set out in the grant letter entered into between the employee and the Company have been met.

(5) 1,059,180 RSUs granted under the March 2023 RSU Grant shall vest as follows:

- 25% shall vest on the first anniversary of the Vesting Commencement Date (rounding to the nearest whole RSU);
- 25% shall vest on the second anniversary of the Vesting Commencement Date (rounding to the nearest whole RSU);
- 25% shall vest on the third anniversary of the Vesting Commencement Date (rounding to the nearest whole RSU); and
- 25% shall vest on the fourth anniversary of the Vesting Commencement Date (rounding to the nearest whole RSU).

1,920,000 RSUs granted under the March 2023 RSU Grant shall vest as follows:

- 25% shall vest on the first anniversary of the Vesting Commencement Date (rounding to the nearest whole RSU); and
- 75% shall vest monthly in equal installments over the 36 months (rounding to the nearest whole RSU) immediately following the first anniversary of the Vesting Commencement Date.

400,000 RSUs granted under the March 2023 RSU Grant shall vest as follows:

- 25% shall vest on the first anniversary of the date of satisfaction of the respective performance target milestone (rounding to the nearest whole RSU);
- 25% shall vest on the second anniversary of the date of satisfaction of the respective performance target milestone (rounding to the nearest whole RSU);
- 25% shall vest on the third anniversary of the date of satisfaction of the respective performance target milestone (rounding to the nearest whole RSU); and
- 25% shall vest on the fourth anniversary of the date of satisfaction of the respective performance target milestone (rounding to the nearest whole RSU).

(6) The vesting commencement date of the 200,000 RSUs granted on October 18, 2024 was October 9, 2024. The 200,000 RSUs shall vest as follows:

- 25% shall vest on the first anniversary of the RSU Vesting Commencement Date (rounding to the nearest whole RSU);
- 25% shall vest on the second anniversary of the RSU Vesting Commencement Date (rounding to the nearest whole RSU);
- 25% shall vest on the third anniversary of the RSU Vesting Commencement Date (rounding to the nearest whole RSU); and
- 25% shall vest on the fourth anniversary of the RSU Vesting Commencement Date (rounding to the nearest whole RSU).

The RSUs granted to the grantee shall vest in several batches, with a total vesting period of more than 12 months. Due to administrative reasons, the period between the date of grant and the first vesting period for the RSUs granted to the grantee is less than 12 months to reflect the time from which the RSUs would have been granted as permitted under specific circumstances as set out in the Post-IPO RSU Scheme. In any event, the Board has the discretion to accelerate the above vesting schedules of the RSUs, subject to compliance with the requirements of Rule 17.03F of the Listing Rules as and when appropriate. The Board was of the view that the grant of RSUs and the relevant vesting periods were appropriate and in line with the market practice and the purposes of the Post-IPO RSU Scheme.

A time-based vesting schedule is applicable to the grant of RSUs with no performance target attached.

(7) The vesting commencement date of the 1,134,000 RSUs granted to Dr. Jianxin Yang and 5,623,200 RSUs granted to other employee participants (including members of senior management) on April 11, 2025 (the "**April 2025 RSU Grant**") was April 2, 2025 (the "**Vesting Commencement Date**"). No performance targets were attached to the April 2025 RSU Grant.

658,200 RSUs granted under the April 2025 RSU Grant shall vest as follows:

- 25% shall vest on the first anniversary of the Vesting Commencement Date (rounding to the nearest whole RSU);
- 25% shall vest on the second anniversary of the Vesting Commencement Date (rounding to the nearest whole RSU);
- 25% shall vest on the third anniversary of the Vesting Commencement Date (rounding to the nearest whole RSU); and
- 25% shall vest on the fourth anniversary of the Vesting Commencement Date (rounding to the nearest whole RSU).

6,099,000 RSUs granted under the April 2025 RSU Grant shall vest as follows:

- 25% shall vest on the first anniversary of the Vesting Commencement Date (rounding to the nearest whole RSU); and
- 75% shall vest monthly in equal installments over the 36 months (rounding to the nearest whole RSU) immediately following the first anniversary of the Vesting Commencement Date.

The RSUs granted to the grantees under the April 2025 RSU Grant will vest in several batches, with a total vesting period of more than 12 months. The period between the date of grant and the first vesting period of the RSUs granted to the grantees are less than 12 months. Having considered, due to administrative reasons and for the purpose of reflecting the time from which the RSUs would have been granted as permitted under specific circumstances as set out in the Post-IPO RSU Scheme, the Board and the Compensation Committee were of the view that the grant of RSUs and the relevant vesting periods are appropriate and in line with market practice and the purposes of the Post-IPO RSU Scheme.

(8) The RSUs under the Post-IPO RSU Scheme were granted to the grantees at nil consideration and were or will be transferred to the grantees upon vesting at nil consideration.

(9) Exercise period is not applicable to RSUs.

(10) The number of Shares that may be issued in respect of RSUs granted under the Post-IPO RSU Scheme during the Reporting Period divided by the weighted average number of Shares in issue (excluding treasury Shares) for the period was 0.51%.

(11) For details of the basis of measurement for the fair value of RSUs granted, please refer to note 19 to the Condensed Consolidated Financial Statements.

For further details of the Share Incentivization Schemes, including the fair value of the options and RSUs granted under the Share Incentivization Schemes, please refer to note 19 to the Condensed Consolidated Financial Statements.

SUMMARY OF THE SHARE INCENTIVIZATION SCHEMES

The major terms and details of the Share Incentivization Schemes are set out below:

Details	Pre-IPO Incentivization Plan	Post-IPO ESOP	Post-IPO RSU Scheme
1. Purpose	To attract, motivate and/or to reward eligible employees, officers, directors, contractor, advisors and consultants of our Group.	To attract and retain employees, to reward eligible participants for their past contribution to the Company, to provide incentives to the eligible participants to further contribute to the Group and to align their interests with the best interests of the Company and the Shareholders as a whole.	To: • recognize the contributions by certain selected participants with an opportunity to acquire a proprietary interest in the Company; • encourage and retain such individuals for the continual operation and development of the Group; • provide additional incentives for them to achieve performance goals; • attract suitable personnel for further development of the Group; and • motivate the selected participants to maximize the value of the Company for the benefits of both the selected participants and the Company, with a view to achieving the objectives of increasing the value of the Group and aligning the interests of the selected participants directly to the Shareholders of the Company through ownership of Shares.

Details	Pre-IPO Incentivization Plan	Post-IPO ESOP	Post-IPO RSU Scheme
2. Participants	Eligible employees include any employee, officer, director, contractor, advisor or consultant of the Group who is notified by the Board that he or she is eligible by reason of their contribution to the Group.	Eligible employees include any employee, officer, director, contractor, advisor or consultant of the Group who is notified by the Board that he or she is an employee eligible by reason of his or her contribution to the Group, to the extent that an offer of an award to or a receipt of such award by him or her is permitted under the applicable laws, rules and regulations or accounting or tax rules and regulations. In the amended rules of the Post-IPO ESOP as adopted on the Amendment Date, eligible participants include (i) employee participant: any employee (whether fulltime or part-time), a director (including executive directors, non-executive directors and independent non-executive directors) of any member of the Group, and any persons who are granted awards under this plan as an inducement to enter into employment contracts with any member of the Group, in each case until such employee shall cease to be an employee with effect from (and including) the date of termination of his or her employment; and (ii) service provider: any persons (nature person or corporate entity) who provide services to the Group on a continuing and recurring basis in the ordinary course of business of the Group which are in the interests of the long term growth of the Group, including independent contractor, consultant and/or advisors for the R&D, product commercialization, marketing, innovation upgrading, strategic/commercial planning on corporate image and investor relations in investment environment of the Company (excluding any placing agents or financial advisers providing advisory services for fundraising, mergers or acquisition, and service providers such as auditors or valuers who provide assurance, or are required to perform their services with impartiality and objectivity).	Eligible persons include any employee of any member of the Group and any consultant, adviser or agent of any member of the Group (including the connected persons (as defined in the Listing Rules) of the Company), who have contributed or will contribute to the growth and development of the Group. In the amended rules of the Post-IPO RSU Scheme as adopted on the Amendment Date, eligible participants include (i) employee participant: any employee (whether full-time or part-time), a director (including executive directors, non-executive directors and independent non-executive directors) of any member of the Group, and any persons who are granted awards under this scheme as an inducement to enter into employment contracts with any member of the Group, in each case until such employee shall cease to be an employee with effect from (and including) the date of termination of his or her employment; and (ii) service provider: any persons (nature person or corporate entity) who provide services to the Group on a continuing and recurring basis in the ordinary course of business of the Group which are in the interests of the long term growth of the Group, including independent contractor, consultant and/or advisors for the R&D, product commercialization, marketing, innovation upgrading, strategic/commercial planning on corporate image and investor relations in investment environment of the Company (excluding any placing agents or financial advisers providing advisory services for fundraising, mergers or acquisition, and service providers such as auditors or valuers who provide assurance, or are required to perform their services with impartiality and objectivity).

Details	Pre-IPO Incentivization Plan	Post-IPO ESOP	Post-IPO RSU Scheme
3. Maximum number of Shares that can be awarded	The maximum number of Shares in respect of which awards may be granted under the plan shall not, subject to any reorganisation of capital structure and other corporate events, exceed 130,831,252 Shares in the aggregate (taken into account of the capitalization issue on the Listing Date).	The maximum number of Shares in respect of which awards may be granted or delivered in satisfaction of awards under the plan shall not, subject to any reorganisation of capital structure and other corporate events, exceed 98,405,153 (taken into account of the capitalization issue on the Listing Date), being 10% of the Shares in issue as of the adoption date. The limit on the number of Shares which may be issued upon exercise of all outstanding options granted and yet to be exercised under the plan and any other schemes must not exceed 30% of the relevant class of Shares in issue from time to time. In the amended rules of the Post-IPO ESOP as adopted on the Amendment Date, the Company shall not make any further grant of options which will result in the aggregate number of Shares underlying all grants of (i) new Shares or restricted share units or restricted shares of the Company; or (ii) options over new Shares made pursuant to this Plan and other share schemes adopted by the Company from time to time to exceed 128,384,401 Shares, representing 10% of the total number of issued Shares as of the Amendment Date without Shareholders' approval (the "**Scheme Mandate Limit**"). Within the Scheme Mandate Limit, the total number of Awards which may be granted under this plan and grants made under other share schemes of the Company to service providers shall not exceed 12,838,440 Shares, representing 1% of the total number of Shares in issue on the Amendment Date (the "**Service Provider Sublimit**").	The Board may not make any further award which will result in the aggregate number of the Shares awarded by the Board under the scheme exceeding, initially, 7,650,000 Shares (being approximately 0.78% of the issued share capital of the Company as at the adoption date), which was subsequently increased to 38,010,316 Shares (being approximately 2.79% of the issued share capital of the Company as at June 30, 2025) pursuant to a board meeting dated July 15, 2019. In the amended rules of the Post-IPO RSU Scheme as adopted on the Amendment Date, the Company shall not make any further grant of restricted new share award which will result in the aggregate number of Shares underlying all grants of (i) new Shares of the Company; or (ii) options over new Shares made pursuant to this scheme and other share schemes adopted by the Company to exceed the Scheme Mandate Limit. Within the Scheme Mandate Limit, the total number of restricted new shares which may be granted under this scheme and grants made under other share schemes of the Company to service providers shall not exceed the Service Provider Sublimit. The maximum number of grant of restricted existing shares under this scheme is 5% of the total issued Shares of the Company as at the Amendment Date (excluding any restricted existing shares lapsed in accordance with term of this scheme).

Details	Pre-IPO Incentivization Plan	Post-IPO ESOP	Post-IPO RSU Scheme
4. Maximum entitlement of each participant	No employee shall be granted an award which, if exercised or settled in full, would result in such employee becoming entitled to subscribe for such number of shares as, when aggregated with the total number of shares already issued under all the awards previously granted to him which have been exercised, and, issuable or settled under all the awards previously granted to him which for the time being subsisting and unexercised, would exceed 10% of the aggregate number of Shares for the time being issued and issuable under the plan.	Except with the approval of the Shareholders in general meeting, no option may be granted to any one person which, if exercised or settled in full, such that the total number of Shares issued and to be issued upon exercise of options and any other option over the Shares (including exercised, cancelled and outstanding options) granted and to be granted to such person in any 12-month period up to the date of the latest grant exceeds 1% of the Shares in issue from time to time. In the amended rules of the Post-IPO ESOP as adopted on the Amendment Date, for any 12-month period up to and including the grant date, the aggregate number of Shares issued and to be issued in respect of all options granted to any eligible participant under this plan and any grants made under any other share scheme(s) of the Company (excluding any options or awards lapsed under any share scheme of the Company) shall not exceed 1% of the total number of the Shares in issue as at the grant date without Shareholders' approval.	In the amended rules of the Post-IPO RSU Scheme as adopted on the Amendment Date, for any 12-month period up to and including the grate date, the aggregate number of Shares issued and to be issued in respect of all restricted new shares granted to any selected participant and all grants made under any other share scheme(s) of the Company (excluding any options and/or awards lapsed in accordance with the share schemes of the Company) shall not exceed 1% of the total number of the Shares in issue as at the grate date without Shareholders' approval. Where any grant of awards to a substantial shareholder of the Company or an independent non-executive Director, or their respective associates, would result in the total number of Shares issued and to be issued in respect of all awards or options granted and to be granted to such person in the 12-month period up to and including the date of such grant (excluding any awards or options lapsed in accordance with the terms of the share schemes of the Company), representing in aggregate over 0.1% of the total number of Shares in issue, such further grant of awards must be approved by the Shareholders in general meeting.
5. Option period	The period during which the option can be exercised as set forth in the relevant offer letters in accordance with the plan.	The period during which the option can be exercised as set forth in the relevant offer letters in accordance with the plan, which, in any event, must end on or before the tenth anniversary of the date of the grant of such option. In the amended rules of the Post-IPO ESOP as adopted on the Amendment Date, the option must be held by the grantee for at least 12 months before the option can be vested save for the exceptional circumstances prescribed in the plan.	The vesting of the awarded Shares is subject to the selected participant remaining at all times after the grant date and on the date of vesting, an eligible person, subject to the rules of the scheme. Save for the circumstances prescribed in the scheme, the vesting period of the restricted new shares granted shall not be less than 12 months.

Details	Pre-IPO Incentivization Plan	Post-IPO ESOP	Post-IPO RSU Scheme
6. Acceptance of offer	Awards granted must be accepted within the period as stated in the offer of the grant, upon payment of exercise price as set out in the relevant offer letter per grant, if any. There is no amount payable solely for application or acceptance of the option or awards.		
7. Exercise price	The subscription price shall be approved by the Board and shall be set out in the offer letter. The exercise prices of the options granted between the adoption date and the Listing Date include US$0.1, US$0.2, US$0.57 and US$2.37 (without taking into account the effect of the capitalisation issue).	The subscription price shall be approved by the Board and shall be set out in the offer letter. The subscription price per Share of each award requiring exercise must be determined in accordance with the Fair Market Value of the Shares subject to the award, determined as of the date of grant. "Fair Market Value" means the higher of (a) the closing price of a Share on the date of grant, which must be a business day, on the principal stock market or exchange on which the Shares are quoted or traded, and (b) the average closing price of a Share for the five trading days immediately preceding the date of grant, on the principal stock market or exchange on which the Shares are quoted or traded, or if Shares are not so quoted or traded, the fair market value of a Share as determined by the Compensation Committee.	–

Details	Pre-IPO Incentivization Plan	Post-IPO ESOP	Post-IPO RSU Scheme
8. Remaining life of the scheme	The plan shall be valid and effective for the period of ten years commencing on the adoption date until July 7, 2027 after which period no further awards will be granted, but the provisions of the plan shall in all other respects remain in full force and effect and the grantees may exercise the options in accordance with the terms upon which the options are granted. The remaining life of the plan is approximately one year and nine months as at the date of this report.	The plan shall be valid and effective for the period of ten years commencing on the adoption date until February 26, 2029 after which period no further awards will be granted, but the provisions of the plan shall in all other respects remain in full force and effect and the grantees may exercise the options in accordance with the terms upon which the options are granted. The remaining life of the plan is approximately three years and five months as at the date of this report.	The scheme remains valid and effective from the adoption date until March 22, 2029, being the tenth anniversary of the adoption date, after which period no further awards will be granted, but the provisions of the scheme will in all other respects remain in full force and effect and awards that are granted from the adoption date until the tenth anniversary of the adoption date may continue to be exercisable in accordance with their terms of issue. The remaining life of the scheme is approximately three years and six months as at the date of this report.

Report on Review of Condensed Consolidated Financial Statements

Deloitte. 德勤

TO THE BOARD OF DIRECTORS OF CSTONE PHARMACEUTICALS
(incorporated in the Cayman Islands with limited liability)

INTRODUCTION

We have reviewed the condensed consolidated financial statements of CStone Pharmaceuticals (the "Company") and its subsidiaries (collectively referred to as the "Group") set out on pages 59 to 80, which comprise the condensed consolidated statement of financial position at June 30, 2025 and the related condensed consolidated statement of profit or loss and other comprehensive income, condensed consolidated statement of changes in equity and condensed consolidated statement of cash flows for the six-month period then ended, and notes to the condensed consolidated financial statements. The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited require the preparation of a report on interim financial information to be in compliance with the relevant provisions thereof and International Accounting Standard 34 *Interim Financial Reporting* ("IAS 34") issued by the International Accounting Standards Board. The directors of the Company are responsible for the preparation and presentation of these condensed consolidated financial statements in accordance with IAS 34. Our responsibility is to express a conclusion on these condensed consolidated financial statements based on our review, and to report our conclusion solely to you, as a body, in accordance with our agreed terms of engagement, and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report.

SCOPE OF REVIEW

We conducted our review in accordance with International Standard on Review Engagements 2410 *Review of Interim Financial Information Performed by the Independent Auditor of the Entity* issued by the International Auditing and Assurance Standards Board. A review of these condensed consolidated financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

CONCLUSION

Based on our review, nothing has come to our attention that causes us to believe that the condensed consolidated financial statements are not prepared, in all material respects, in accordance with IAS 34.

Deloitte Touche Tohmatsu
Certified Public Accountants
Hong Kong
August 14, 2025

Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income

For the Six Months Ended June 30, 2025

	NOTES	For the six months ended June 30, 2025 RMB'000 (Unaudited)	2024 RMB'000 (Unaudited)
Revenue	3	**49,451**	254,165
Cost of revenue		**(142,241)**	(82,136)
Gross (loss) profit		**(92,790)**	172,029
Other income	4	**9,315**	14,824
Other gains and losses	4	**4,566**	12,884
Research and development expenses		**(105,166)**	(66,248)
Selling and marketing expenses		**(35,654)**	(62,769)
Administrative expenses		**(43,546)**	(46,672)
Finance costs		**(6,908)**	(8,349)
(Loss) profit for the period	6	**(270,183)**	15,699
Other comprehensive income (expense):			
Item that may be reclassified subsequently to profit or loss:			
Exchange differences arising on translation of foreign operations		**269**	(11)
Total comprehensive (expense) income for the period		**(269,914)**	15,688
(Loss) earnings per share	8		
– Basic (RMB)		**(0.21)**	0.01
– Diluted (RMB)		**(0.21)**	0.01

Condensed Consolidated Statement of Financial Position

At June 30, 2025

	NOTES	June 30, 2025 RMB'000 (Unaudited)	December 31, 2024 RMB'000 (Audited)
Non-current assets			
Property, plant and equipment	9	**88,624**	93,218
Right-of-use assets		**21,361**	37,325
Intangible assets		**155,526**	161,366
Financial assets measured at fair value through profit or loss ("FVTPL")	13	**4,847**	9,032
Other receivables	12	**20,058**	2,617
		290,416	303,558
Current assets			
Account receivables	10	**62,536**	83,929
Deposits, prepayments and other receivables	12	**37,336**	46,946
Inventories		**148,851**	286,096
Time deposits with original maturity over three months	14	**195,000**	285,000
Cash and cash equivalents	14	**457,766**	387,937
		901,489	1,089,908
Current liabilities			
Account and other payables and accrued expenses	15	**387,690**	576,181
Refund liabilities		**7,774**	2,224
Bank borrowings	17	**194,000**	60,800
Contract liabilities	16	**10,385**	10,385
Lease liabilities		**25,947**	32,416
		625,796	682,006
Net current assets		**275,693**	407,902
Total assets less current liabilities		**566,109**	711,460

Condensed Consolidated Statement of Financial Position

At June 30, 2025

	NOTES	June 30, 2025 RMB'000 (Unaudited)	December 31, 2024 RMB'000 (Audited)
Non-current liabilities			
Bank borrowings	17	**169,200**	257,400
Contract liabilities	16	**79,639**	84,832
Lease liabilities		**2,226**	5,357
		251,065	347,589
Net assets		**315,044**	363,871
Capital and reserves			
Share capital	18	**918**	860
Treasury shares held in the trust	18	**(4)**	(7)
Reserves		**314,130**	363,018
Total equity		**315,044**	363,871

Condensed Consolidated Statement of Changes in Equity

For the Six Months Ended June 30, 2025

	Share capital *RMB'000*	Share premium *RMB'000*	Other reserves *RMB'000*	Treasury shares held in the trust *RMB'000*	Share-based payment reserve *RMB'000*	Foreign currency translation reserve *RMB'000*	Accumulated losses *RMB'000*	Total *RMB'000*
At January 1, 2024 (Audited)	860	8,992,459	(92,732)	(8)	579,020	(3,042)	(9,019,727)	456,830
Profit for the period	–	–	–	–	–	–	15,699	15,699
Other comprehensive expense for the period	–	–	–	–	–	(11)	–	(11)
Total comprehensive (expense) income for the period	–	–	–	–	–	(11)	15,699	15,688
Restricted stock units exercised under trust (note 18)	–	7,731	(1)	1	(7,731)	–	–	–
Recognition of equity-settled share-based payment (note 19)	–	–	–	–	(4,889)	–	–	(4,889)
Exercise of share options (note 19)	–	201	–	–	(174)	–	–	27
At June 30, 2024 (Unaudited)	860	9,000,391	(92,733)	(7)	566,226	(3,053)	(9,004,028)	467,656
At January 1, 2025 (Audited)	**860**	**9,003,959**	**(92,733)**	**(7)**	**564,783**	**(2,057)**	**(9,110,934)**	**363,871**
Loss for the period	**–**	**–**	**–**	**–**	**–**	**–**	**(270,183)**	**(270,183)**
Other comprehensive income for the period	**–**	**–**	**–**	**–**	**–**	**269**	**–**	**269**
Total comprehensive income (expense) for the period	**–**	**–**	**–**	**–**	**–**	**269**	**(270,183)**	**(269,914)**
Restricted stock units exercised under trust (note 18)	**–**	**8,316**	**(3)**	**3**	**(8,316)**	**–**	**–**	**–**
Recognition of equity-settled share-based payment (note 19)	**–**	**–**	**–**	**–**	**5,084**	**–**	**–**	**5,084**
Exercise of share options (note 19)	**–**	**488**	**–**	**–**	**(309)**	**–**	**–**	**179**
Issue of ordinary shares (note 18)	**58**	**215,766**	**–**	**–**	**–**	**–**	**–**	**215,824**
At June 30, 2025 (Unaudited)	**918**	**9,228,529**	**(92,736)**	**(4)**	**561,242**	**(1,788)**	**(9,381,117)**	**315,044**

Condensed Consolidated Statement of Cash Flows

For the Six Months Ended June 30, 2025

	For the six months ended June 30,	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
OPERATING ACTIVITIES		
(Loss) profit for the period	**(270,183)**	15,699
Adjustments for non-cash or non-operating items	**99,237**	5,097
Operating cash flows before movements in working capital	**(170,946)**	20,796
Interest received	**1,206**	736
Decrease (increase) in account receivables	**16,994**	(6,656)
Increase in deposits, prepayments and other receivables	**(10,242)**	(22,625)
Decrease (increase) in inventories	**72,344**	(69,239)
Decrease in account and other payables and accrued expenses	**(189,218)**	(90,968)
Increase (decrease) in refund liabilities	**5,550**	(19,176)
NET CASH USED IN OPERATING ACTIVITIES	**(274,312)**	(187,132)
INVESTING ACTIVITIES		
Interest received	**3,152**	6,703
Receipt of return from money market funds	**136**	196
Proceeds on disposal of financial asset measured at FVTPL	**1,568**	–
Withdrawal of time deposits with maturity over three months	**90,000**	–
Placement of time deposits with maturity over three months	**–**	(105,000)
Proceeds on disposal of property, plant and equipment	**–**	372
NET CASH FROM (USED IN) INVESTING ACTIVITIES	**94,856**	(97,729)
FINANCING ACTIVITIES		
Interest paid	**(5,156)**	(6,720)
Repayment of lease liabilities	**(10,098)**	(16,216)
Exercise of share options	**179**	27
Proceeds from bills receivables discounted to banks	**4,396**	–
New bank borrowings raised	**150,000**	178,000
Repayments of bank borrowings	**(105,000)**	(190,564)
Proceeds on issue of ordinary shares	**218,004**	–
Transaction costs attributable to issue of shares	**(2,180)**	–
NET CASH FROM (USED IN) FINANCING ACTIVITIES	**250,145**	(35,473)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	**70,689**	(320,334)
Effect of foreign exchange rate changes	**(860)**	2,519
CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD	**387,937**	996,671
TOTAL CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD	**457,766**	678,856

1. GENERAL AND BASIS OF PREPARATION

CStone Pharmaceuticals (the "Company") is a public limited company incorporated in the Cayman Islands and its shares are listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "Stock Exchange") since February 26, 2019.

The condensed consolidated financial statements have been prepared in accordance with International Accounting Standard 34 *Interim Financial Reporting* issued by the International Accounting Standards Board ("IASB") as well as the applicable disclosure requirements of the Rules Governing the Listing of Securities on The Stock Exchange.

The directors of the Company have, at the time of approving the condensed consolidated financial statements, a reasonable expectation that the Group has adequate resources to continue in operational existence for the foreseeable future. Thus they continue to adopt the going concern basis of accounting in preparing the condensed consolidated financial statements.

2. ACCOUNTING POLICIES

The condensed consolidated financial statements have been prepared on the historical cost basis except for certain financial instruments, which are measured at fair values, as appropriate.

Other than change in accounting policies resulting from application of amendments to IFRS Accounting Standards issued by IASB, the accounting policies and methods of computation used in the condensed consolidated financial statements for the six months ended June 30, 2025 are the same as those presented in the Group's annual consolidated financial statements for the year ended December 31, 2024.

Application of amendments to IFRS Accounting Standards

In the current interim period, the Group has applied the following amendments to IFRS Accounting Standard issued by the IASB, for the first time, which are mandatory effective for the Group's annual period beginning on January 1, 2025 for the preparation of the Group's condensed consolidated financial statements:

Amendments to IAS 21	Lack of Exchangeability

The application of the amendment to IFRS Accounting Standards in the current interim period has had no material impact on the Group's financial positions and performance for the current and prior periods and/or on the disclosures set out in these condensed consolidated financial statements.

3. REVENUE AND SEGMENT INFORMATION

Disaggregation of revenue from contracts with customers

	For the six months ended June 30	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Types of goods or services		
Sales of pharmaceutical products	**20,216**	118,279
License fee income	**17,934**	122,567
Royalty income	**11,301**	13,319
	49,451	254,165
Timing of revenue recognition		
A point in time	**49,451**	254,165

Segment Information

The Group has been operating in one reportable segment, being the research and development of highly complex biopharmaceutical products, sale of pharmaceutical products, and provide license of its intellectual property or commercialisation license to customers.

The Group's chief operating decision maker ("CODM") has been identified as the chief executive officer of the Group. For the purpose of resource allocation and performance assessment, the CODM reviews the overall results and financial position of the Group prepared based on the Group's accounting policies.

Geographical Information

Substantially, majority of the Group's operation and non-current assets are located in the People's Republic of China (the "PRC"). The geographical information of the Group's revenue, determined based on the geographical location of the registered office of the customers, during the reporting period is as follows:

	For the six months ended June 30	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Mainland China	**26,942**	232,106
Outside Mainland China	**22,509**	22,059
	49,451	254,165

4. OTHER INCOME AND OTHER GAINS AND LOSSES

Other income

	For the six months ended June 30,	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Bank and other interest income	**1,087**	7,439
Government grants income *(note a)*	**2,712**	525
Amortisation of payments received for exclusive promotion rights granted *(note b)*	**5,193**	3,443
Income from sales of scrap materials	**–**	2,723
Others	**323**	694
	9,315	14,824

Notes:

a. Government grants include subsidies from the PRC government related to income that are receivable as compensation for expenses or losses already incurred or for the purpose of giving immediate financial support to the Group with no future related costs are recognised in profit or loss in the period in which they become receivable.

b. The amount represents the amortisation of advance payments received to grant the promotion rights to the independent third parties on the pharmaceutical products over the agreed exclusive promotion period as detailed in note 16.

Other gains and losses

	For the six months ended June 30,	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Net gain on fair value changes of money market funds	**136**	196
Net (loss) gain on fair value changes of financial assets measured at FVTPL	**(2,617)**	9,132
Net foreign exchange gains	**7,021**	3,235
Gain on disposal of property, plant and equipment	**–**	340
Others	**26**	(19)
	4,566	12,884

5. INCOME TAX EXPENSE

No income tax expense for the six months ended June 30, 2025 and 2024 as the Group had no assessable profits derived from the operating entities of the Group.

6. (LOSS) PROFIT FOR THE PERIOD

	For the six months ended June 30,	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
(Loss) profit for the period has been arrived at after charging (crediting):		
Depreciation of		
Property, plant and equipment	**291**	1,043
Right-of-use assets	**15,964**	17,125
Amortisation of intangible assets	**5,840**	5,839
Total depreciation and amortisation	**22,095**	24,007
Directors' emoluments	**10,909**	15,423
Other staff costs:		
Salaries and other allowances	**34,523**	52,501
Performance related bonus	**11,249**	3,986
Retirement benefit scheme contributions	**7,475**	12,370
Share-based payment expenses	**(1,525)**	(16,927)
	51,722	51,930
	62,631	67,353
Impairment losses recognised on construction in progress (included in research and development expenses)	**4,303**	4,161
Write-down (reversal) of inventories (included in cost of revenue)	**64,901**	(2,710)
Cost of inventories recognised as cost of revenue	**53,181**	43,529

7. DIVIDENDS

No dividends were paid, declared or proposed for ordinary shareholders of the Company during the interim period, nor has any dividend been proposed since the end of the reporting period.

8. (LOSS) EARNINGS PER SHARE

The calculation of the basic and diluted (loss) earnings per share for the period is as follows:

	For the six months ended June 30,	
	2025 (Unaudited)	2024 (Unaudited)
(Loss) earnings (RMB'000)		
(Loss) earnings for the period attributable to owners of the Company for the purpose of basic and diluted (loss) earnings per share	**(270,183)**	15,699
Number of shares ('000)		
Weighted average number of ordinary shares for the purpose of basic and diluted (loss) earnings per share	**1,314,139**	1,275,512

The calculation of basic and diluted (loss) earnings per share for both periods has excluded the treasury shares held in trust of the Company.

Diluted (loss) earnings per share for both periods did not assume the exercise of share options awarded under the employee stock option and the vesting of unvested restricted stock units (note 19) as their inclusion would be anti-dilutive.

9. PROPERTY, PLANT AND EQUIPMENT

During the current interim period, no addition or disposal of property, plant and equipment incurred (six months ended June 30, 2024: disposed of RMB32,000).

During the current interim period, in view that CStone Suzhou Factory (the "Facilities") remained temporary suspension of the operation, the directors of the Company have performed an impairment assessment of the Facilities and consequently determined an impairment of the related construction in progress amounting to RMB4,303,000 (six months ended June 30, 2024: RMB4,161,000). The impairment loss has been included in profit or loss in the research and development expenses line item.

10. ACCOUNT RECEIVABLES

The Group allows an average credit period of 60 days to its customers.

The following is an aged analysis of account receivables presented based on invoice dates at the end of the reporting period.

	June 30, 2025 ***RMB'000*** **(Unaudited)**	December 31, 2024 *RMB'000* (Audited)
0 – 60 days	**24,923**	48,688
61 – 90 days	**1,827**	–
Over 90 days	**35,786**	35,241
	62,536	83,929

11. TRANSFERS OF FINANCIAL ASSETS

At June 30, 2025, the Group had derecognised bills discounted to banks on a full recourse basis amounting to RMB4,399,000 (December 31, 2024: RMB40,000,000). These bills were issued or guaranteed by reputable PRC banks with high credit ratings, therefore the directors of the Company considered the substantial risks in relation to these bills were interest risk as the credit risk arising from these bills were minimal, the Group had transferred substantially all the risks of these bills to relevant banks. However, if the bills cannot be accepted at maturity, the banks have the right to require the Group pay off the outstanding balance. Therefore, the Group continued involve in them. Such bills are matured and settled in July 2025.

12. DEPOSITS, PREPAYMENTS AND OTHER RECEIVABLES

	June 30, 2025 RMB'000 (Unaudited)	December 31, 2024 RMB'000 (Audited)
Rental deposits	**9,587**	9,587
Prepayments	**4,772**	2,374
Value-added tax ("VAT") recoverable	**7,801**	2,442
Reimbursement from a licensor *(note i)*	**–**	21,364
Other receivable from a customer *(note ii)*	**21,703**	–
Interest receivables	**7,947**	10,358
Others	**5,584**	3,438
	57,394	49,563
Analysed as:		
Non-current	**20,058**	2,617
Current	**37,336**	46,946
	57,394	49,563

Notes:

(i) The Group entered in an agreement with the licensor and its authorised manufacturer. Amounts represented the balance in which the Group is entitled to receive from the licensor pursuant to which the licensor will reimburse to the Group for part of the Group's cost of purchase from authorised manufacturer. Such amounts are fully settled during the current interim period.

(ii) Amount represents the balance in which the Group is entitled to be reimbursed from its customer.

13. FINANCIAL ASSETS MEASURED AT FVTPL

	June 30, 2025 RMB'000 (Unaudited)	December 31, 2024 RMB'000 (Audited)
Unlisted equity investment	**4,847**	4,868
Listed equity investment	**–**	4,164
	4,847	9,032

13. FINANCIAL ASSETS MEASURED AT FVTPL (continued)

Note: At June 30, 2025 and December 31, 2024, the Group held 500,000 Class X units of a private equity after the redemption of the fund linked note as detailed in note 19 of the annual report of the Group's for the year ended December 31, 2022. Pursuant to the amended agreement of the private equity, the distribution of class B shares of the unlisted entity are made to the holders of Class X units while class B shares of the unlisted entity are automatically converted into the class A shares of the unlisted entity upon the completion of business combination. During the current interim period, the Group disposed of the remaining class A shares which were transferred from the prior year. The management of the Group assessed its fair value of Class X units of the private equity is nil at June 30, 2025 and December 31, 2024, after considering the expected return of the underlying investments.

14. CASH AND CASH EQUIVALENTS AND TIME DEPOSITS

Time deposits with original maturity over three months

At June 30, 2025, the Group held time deposits of RMB195,000,000 (December 31, 2024: RMB285,000,000) with original maturity of 3 years which carried effective interest rates ranging from 2.35% to 3.10% (December 31, 2024: from 2.15% to 3.10%) per annum. The management intends to hold such time deposits within a business model whose objective is achieved by both collecting contractual cash flows and selling the financial assets.

Cash and cash equivalents

	June 30, 2025 ***RMB'000*** **(Unaudited)**	December 31, 2024 *RMB'000* (Audited)
Cash at banks	**359,635**	381,501
Cash on hand	**71**	71
Cash equivalents		
– Money market funds *(note)*	**6,474**	6,365
– Time deposits with original maturity less than three months	**91,586**	–
	457,766	387,937

Note: Amount represents investments money market fund with low volatility.

15. ACCOUNT AND OTHER PAYABLES AND ACCRUED EXPENSES

	June 30, 2025 *RMB'000* (Unaudited)	December 31, 2024 *RMB'000* (Audited)
Account payables *(note b)*	**212,085**	338,029
Accrued expenses		
– Research and development *(note a)*	**67,415**	112,898
– Royalty fees	**23,942**	19,797
– Selling and marketing	**18,623**	31,354
– Legal and professional fees	**2,634**	882
– Others	**9,981**	1,985
Staff payroll payables	**22,481**	28,314
Other tax payable	**1,428**	1,774
Other payables	**29,101**	41,148
	175,605	238,152
	387,690	576,181

Notes:

(a) Amounts mainly included accrued service fees to outsourced the service providers including contract research organisations, contract manufactory organisations and clinical trial centres.

(b) In 2023, the Group entered into a supplemental agreement with the vendors, pursuant to which both parties agreed to defer an amount of RMB24,987,000 and US$7,945,000. Such amounts are carried at a fixed interest rate of 4% per annum. Pursuant to the supplemental agreement, the repayment schedule is US$1,000,000 to be settled in the first quarter of 2024, and US$3,000,000 in total to be settled in the third quarter of 2024 and the first quarter of 2025, the remaining principal and interest to be settled in the third quarter of 2025. During the year ended December 31, 2024, the Group settled RMB7,020,000 and the vendor waived RMB4,639,000. No amounts were settled during the current interim period. At June 30, 2025, outstanding balance of US$3,000,000 (equivalent to RMB21,476,000) were due for payment in accordance with the repayment schedule and RMB54,874,000 are scheduled to be settled in the third quarter of 2025.

15. ACCOUNT AND OTHER PAYABLES AND ACCRUED EXPENSES (continued)

The credit period on account payables is ranged from 0 to 90 days except for those set out in the abovementioned in note (b). The following is an aged analysis of account payables presented based on invoice dates at the end of the reporting period.

	June 30, 2025 ***RMB'000*** **(Unaudited)**	December 31, 2024 *RMB'000* (Audited)
0 – 30 days	**47,336**	74,545
31 – 60 days	**16,635**	142,635
61 – 90 days	**6,227**	24,848
Over 90 days	**141,887**	96,001
	212,085	338,029

16. CONTRACT LIABILITIES

	June 30, 2025 ***RMB'000*** **(Unaudited)**	December 31, 2024 *RMB'000* (Audited)
Advance from customers for exclusive promotion rights	**90,024**	95,217
Analysed as:		
Non-current	**79,639**	84,832
Current	**10,385**	10,385
	90,024	95,217

The Group entered into exclusive promotion service agreement with the independent third parties pursuant to which the Group is entitled to receive the upfront payment and additional milestone payments, while the counterparties receive the exclusive rights to commercialise the Group's pharmaceutical product in China and receives tiered service fee based on the net sales. The VAT-excluded amount was recognised in contract liabilities and will be amortised over the agreed exclusive promotion period.

17. BANK BORROWINGS

During the current interim period, the Group obtained new bank borrowings of RMB100,000,000 (June 30, 2024: RMB178,000,000) which are unsecured, unguaranteed and carried at variable interest rate (also being the effective interest rate) ranging from Loan Prime Rate ("LPR") less 65 basis points to LPR less 60 basis points (June 30, 2024: 45) per annum, for the purpose of working capital. Additionally, the Group also obtained new bank borrowings of RMB50,000,000 (six months ended June 30, 2024: nil) which are unsecured, unguaranteed and carried at fixed rate ranged from 2.6% to 2.9% (June 30, 2024: nil) per annum for the purpose of working capital. The Group repaid bank loans of RMB105,000,000 (six months ended June 30, 2024: RMB190,564,000).

In respect of non-current bank borrowings with carrying amount of RMB98,000,000 as at June 30, 2025 (December 31, 2024: RMB145,000,000), the Group has complied with the relevant covenants at each test date on or before the end of the reporting period.

18. SHARE CAPITAL/TREASURY SHARES HELD IN THE TRUST

	Number of shares	Share capital *US$'000*
Ordinary shares		
Ordinary shares of US$0.0001 each		
Authorised		
At January 1, 2024 (Audited), June 30, 2024 (Unaudited), January 1, 2025 (Audited) and June 30, 2025 (Unaudited)	2,000,000,000	200

	Number of shares	Amount *US$'000*	Equivalent amount of ordinary shares *RMB'000*
Issued and fully paid			
At January 1, 2024 (Audited)	1,284,163,999	129	860
Exercise of share options	27,213	–*	–*
At June 30, 2024 (Unaudited)	1,284,191,212	129	860
At January 1, 2025 (Audited)	1,284,237,212	129	860
Exercise of share options	264,123	–*	–*
Issuance of ordinary shares	80,000,000	8	58
At June 30, 2025 (Unaudited)	1,364,501,335	137	918

* Amount less than US$1,000 or RMB1,000

18. SHARE CAPITAL/TREASURY SHARES HELD IN THE TRUST (continued)

Treasury shares held in the trust:

	Number of treasury shares	Amount *US$'000*	Equivalent amount of treasury shares *RMB'000*
At January 1, 2024 (Audited)	8,847,286	1	8
RSUs exercised under the trust	(1,112,859)	–*	(1)
At June 30, 2024 (Unaudited)	7,734,427	1	7
At January 1, 2025 (Audited)	7,314,374	1	7
RSUs exercised under the trust	(3,701,125)	–*	(3)
At June 30, 2025 (Unaudited)	3,613,249	1	4

* Amount less than US$1,000

In July 2019, the Company and Computershare Hong Kong Trustees Limited (the "Computershare Trustees"), an independent third party, set up the 2019 CStone Share Incentivisation Trust for Non-Connected Persons which entered into a trust deed pursuant to which the Computershare Trustees has agreed to act as the trustee to administer the Post-IPO RSUs Plan (as defined in note 19(ii)) to hold the ordinary shares under the Post-IPO RSUs Plan through the Computershare Trustees. Since the Company has control over the trust, the shares held in the trust are accounted for as treasury shares of the Company.

19. SHARE-BASED PAYMENT TRANSACTIONS

(i) Employee stock option plan ("ESOP")

The Pre-IPO ESOP

The Group granted share options under its employee stock option plan (the "Pre-IPO ESOP") which was adopted and approved on July 7, 2017 and amended on August 3, 2018 (the "Pre-IPO Incentivisation Plan") for the purpose of incentivising, retaining and rewarding certain employees and board members of the Company or its subsidiaries for their contributions to the Group's business, and to align their interests with those of the Group.

19. SHARE-BASED PAYMENT TRANSACTIONS (continued)

(i) Employee stock option plan ("ESOP") (continued)

The Pre-IPO ESOP (continued)

The following table discloses movements of the Company's Pre-IPO ESOP held by grantees during the period:

Option type	Outstanding at 1/1/2025 (Audited)	Forfeited	Exercised	Outstanding at 30/6/2025 (Unaudited)
Pre-IPO ESOP	**4,702,487**	**(172)**	**(143,356)**	**4,558,959**
Weighted average exercise price		**USD0.14**	**USD0.05**	
Exercisable	4,702,487			4,558,959

Option type	Outstanding at 1/1/2024 (Audited)	Forfeited	Exercised	Outstanding at 30/6/2024 (Unaudited)
Pre-IPO ESOP	4,989,538	(12,156)	(27,213)	4,950,169
Weighted average exercise price		USD0.14	USD0.04	
Exercisable	4,989,538			4,950,169

The Post-IPO ESOP

Pursuant to a resolution passed on January 30, 2019, the directors of the Company further adopted an employee equity plan (the "Post-IPO ESOP") to grant option awards to any employee, officer, director, contractor, advisor or consultant of the Group by reason of his or her contribution to the Group.

During the current interim period, the Company granted 15,766,800 share options, including 2,646,000 shares options granted to a director and 13,120,800 shares options granted to employees of the Company. The share options are non-performance-based, whereas 25% of the shares will be vested on the first anniversary of the original vesting commencement date, and the remaining 75% shares will be vested with equal monthly instalments over the following 36 months.

19. SHARE-BASED PAYMENT TRANSACTIONS (continued)

(i) Employee stock option plan ("ESOP") (continued)

The Post-IPO ESOP (continued)

The following table discloses movements of the Company's Post-IPO ESOP held by grantees during the period:

Option type	Outstanding at 1/1/2025	Granted	Exercised	Forfeited	Outstanding at 30/6/2025
Post-IPO ESOP	**82,547,155**	**15,766,800**	**(120,767)**	**(4,154,554)**	**94,038,634**
Weighted average exercise price		**HK$2.41**	**HK$1.38**	**HK$6.45**	
Exercisable	20,776,651				22,155,253

Option type	Outstanding at 1/1/2024	Granted	Forfeited	Outstanding at 30/6/2024
Post-IPO ESOP	73,147,494	11,202,900	(5,464,093)	78,886,301
Weighted average exercise price		HK$1.73	HK$4.60	
Exercisable	10,528,601			16,141,320

During the six months ended June 30, 2025, the fair values of the Post-IPO ESOP granted determined at the dates of grant ranged from HK$1.15 to HK$1.53 per share.

The fair value was calculated using Option Pricing Model for both reporting periods. The key assumptions, such as risk free interest rate and volatility, are required to be determined by the directors of the Company with best estimate.

The key inputs into the model for the grants during the periods ended June 30, 2024 and 2025 were as follows:

	For the six months ended June 30, 2025	For the six months ended June 30, 2024
Exercise price	**HK$2.41**	HK$0.94 -HK$2.35
Expected life	**10 years**	10 years
Expected volatility	**62.93%**	56.8%-60.0%
Expected dividend yield	**0%**	0%
Risk-free interest rate	**3.33%**	3.46%-3.76%

19. SHARE-BASED PAYMENT TRANSACTIONS (continued)

(ii) RSUs

The Post-IPO RSUs Plan

A restricted share award scheme (the "Post-IPO RSUs Plan") was approved and adopted pursuant to a resolution passed on March 22, 2019. The directors of the Company may, from time to time, at its absolute discretion grant RSUs to an eligible person in accordance with the Post-IPO RSU Plan.

During the current interim period, the Company granted 6,757,200 RSUs, including 1,134,000 RSUs granted to a director and 5,623,200 RSUs granted to employees of the Company. The RSUs are non-performance-based, whereas 25% of total RSUs vesting on the anniversary date one year after the vesting commencement date and the remaining 75% vesting subsequently in 36 equal monthly instalments or with 25%, 25%, 25% and 25% of total RSUs vesting on the first, second, third and fourth anniversary date one year after the vesting commencement date.

The following table discloses the movement of the Company's Post-IPO RSUs during the period:

	Number of RSUs	
	2025	2024
At January 1, (Audited)	**12,687,382**	4,586,778
Granted	**6,757,200**	11,197,900
Forfeited	**(73,875)**	(1,253,169)
Vested	**(3,701,125)**	(1,112,859)
At June 30, (Unaudited)	**15,669,582**	13,418,650

The fair value of the Post-IPO RSUs granted during the current interim period was HK$2.39 per Post-IPO RSU which was determined by the observable market price at grant date.

20. FAIR VALUE MEASUREMENTS OF FINANCIAL INSTRUMENTS

Fair value measurements and valuation processes

In estimating the fair value, the Group uses market-observable data to the extent it is available. For instruments with significant unobservable inputs under Level 3, the Chief Financial Officer of the Group establishes the appropriate valuation techniques and inputs to the model and reports any findings to the directors of the Company.

20. FAIR VALUE MEASUREMENTS OF FINANCIAL INSTRUMENTS (continued)

Fair value measurements and valuation processes (continued)

The fair values of these financial assets are determined (in particular, the valuation techniques and inputs used), as well as the level of the fair value hierarchy into which the fair value measurements are categories (Levels 1 to 3) based on the degree to which the inputs to the fair value measurements is observable.

- Level 1 fair value measurements are based on quoted prices (unadjusted) in active market for identical assets or liabilities that the entity can access at the measurement date;
- Level 2 fair value measurements are those derived from inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and
- Level 3 fair value measurements are those derived from valuation techniques that include the lowest level inputs for the asset or liability that are not based on observable market data (unobservable inputs).

Fair value of the Group's financial assets that are measured at fair value on a recurring basis

Financial assets	Fair value at		Fair value hierarchy	Valuation techniques and key input(s)
	June 30, 2025 ***RMB'000*** **(Unaudited)**	December 31, 2024 *RMB'000* (Audited)		
Money market funds	**6,474**	6,365	Level 2	Based on the net asset values of the funds, which are determined with reference to observable and quoted prices of underlying investment portfolio and adjustments of related expenses
Unlisted equity investment	**4,847**	4,868	Level 2	Recent transaction price
Listed equity investment	**–**	4,164	Level 1	Quoted closing prices in an active market
Time deposits with original maturity over three months measured at FV	**195,000**	285,000	Level 2	Discounted cash flows, estimated based on expected return

20. FAIR VALUE MEASUREMENTS OF FINANCIAL INSTRUMENTS (continued)

Fair value of the Group's financial assets that are measured at fair value on a recurring basis (continued)

There were no transfers between Level 1 and 2 during the period.

The directors of the Company consider that the carrying amount of the Group's financial assets and liabilities recorded at amortised cost in the condensed consolidated financial statements approximate their fair values.

21. RELATED PARTY TRANSACTIONS

The Group entered into the following transactions during the period with its related parties.

Compensation of key management personnel

The remuneration of directors of the Company and other members of key management were as follows:

	For the six months ended June 30,	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Short term benefits	**11,569**	11,450
Retirement benefits scheme contributions	**485**	546
Total cash compensation	**12,054**	11,996
Share-based payment expense	**11,898**	16,342
	23,952	28,338

The remuneration of key management personnel of the Group is determined by the directors of the Company having regard to the performance of individuals and market trends.

22. EVENTS AFTER THE REPORTING PERIOD

On July 16, 2025, the Company completed the placing of 100,000,000 placing shares by a placing agent to not less than six placees at the placing price of HK$4.72 per placing share, representing 6.83% of the issued share capital of the Company as enlarged by the allotment and issue of the placing shares immediately upon completion of the placing. The Company received net proceeds from the placing, after deducting the placing commission and other related expenses and professional fees, of approximately HK$467.28 million (equivalent to RMB425.79 million).

Definitions

In this report, unless the context otherwise requires, the following terms have the following meanings. These terms and their definitions may not correspond to any industry standard definitions, and may not be directly comparable to similarly titled terms adopted by other companies operating in the same industries as our Company.

"Amendment Date"	means	March 7, 2023, being the date on which the amendments of the Post-IPO ESOP and the Post-IPO RSU Scheme are conditionally approved by resolutions of the Company in its general meeting
"Articles" or "Articles of Association"	means	the sixth amended and restated articles of association of the Company adopted on June 18, 2024, as amended, supplemented or otherwise modified from time to time
"Audit Committee"	means	the audit committee of the Board
"Board", "our Board" or "Board of Directors"	means	the board of Directors
"Board Committees"	means	the Audit Committee, the Nomination Committee, the Compensation Committee, the Strategy Committee and the Investment Committee
"CAGR"	means	compound annual growth rate
"CEO"	means	chief executive officer of the Company
"CG Code"	means	the Corporate Governance Code set out in Appendix C1 to the Listing Rules
"Chairman"	means	the chairman of the Board
"China" or "PRC"	means	the People's Republic of China, for the purposes of this report only, excluding Hong Kong and Macau Special Administrative Region and Taiwan
"Companies Ordinance"	means	the Companies Ordinance (Chapter 622 of the Laws of Hong Kong), as amended, supplemented or otherwise modified from time to time
"Company", "CStone" or "our Company"	means	CStone Pharmaceuticals (stock code: 2616), an exempted company with limited liability incorporated under the laws of the Cayman Islands on December 2, 2015, the Shares of which are listed on the Main Board of the Stock Exchange
"Compensation Committee"	means	the compensation committee of the Board
"Condensed Consolidated Financial Statements"	means	the condensed consolidated financial statements of the Group

Definitions

"CRO(s)"	means	contract research organization, a company that provides support to the pharmaceutical, biotechnology, and medical device industries in the form of research services outsourced on a contract basis
"CStone Suzhou"	means	CStone Pharmaceuticals (Suzhou) Co., Ltd. (基石藥業(蘇州)有限公司), a company established under the laws of the PRC on April 21, 2016 and one of the Company's subsidiaries
"CTA"	means	clinical trial agreement
"Director(s)"	means	the director(s) of our Company
"GIST"	means	gastrointestinal stromal tumor, a type of tumor that occurs in the gastrointestinal tract, most commonly in the stomach or small intestine
"Global Offering"	means	the Hong Kong public offering and the international offering of the Shares
"Group", "our Group", "the Group", "we", "us", or "our"	means	the Company and its subsidiaries from time to time
"HCC"	means	hepatocellular carcinoma, a type of cancer arising from hepatocytes in predominantly cirrhotic liver
"HKD" or "HK$" or "HK dollars"	means	Hong Kong Dollars, the lawful currency of Hong Kong
"Hong Kong" or "HK"	means	the Hong Kong Special Administrative Region of the PRC
"IND"	means	investigational new drug or investigational new drug application, also known as clinical trial application in China or clinical trial notification in Australia
"Independent Auditor" or "Deloitte"	means	Deloitte Touche Tohmatsu
"INED(s)"	means	the independent non-executive Director(s)
"Investment Committee"	means	the investment committee of the Board
"IO"	means	immuno-oncology
"IPO"	means	the initial public offering of the Company on the Stock Exchange
"Listing"	means	the listing of the Shares on the Main Board of the Stock Exchange

"Listing Date"	means	February 26, 2019, being the date on which the Shares were listed on the Main Board of the Stock Exchange
"Listing Rules"	means	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, as amended, supplemented or otherwise modified from time to time
"Main Board"	means	the stock exchange (excluding the option market) operated by the Stock Exchange, which is independent from and operated in parallel with the GEM of the Stock Exchange. For the avoidance of doubt, the Main Board excludes the GEM
"Memorandum" or "Memorandum of Association"	means	the sixth amended and restated memorandum of association of the Company adopted on June 18, 2024, as amended, supplemented or otherwise modified from time to time
"Model Code"	means	the Model Code for Securities Transactions by Directors of Listed Issuers contained in Appendix C3 to the Listing Rules
"NDA"	means	new drug application
"NMPA"	means	National Medical Products Administration (國家藥品監督管理局) and its predecessor, the China Food and Drug Administration (國家食品藥品監督管理總局)
"Nomination Committee"	means	the nomination committee of the Board
"Pfizer"	means	Pfizer Inc., a company incorporated in Delaware and listed on the New York Stock Exchange (NYSE: PFE)
"Pfizer Corporation"	means	Pfizer Corporation Hong Kong Limited, a company incorporated in Hong Kong with limited liability, an indirectly wholly-owned subsidiary of Pfizer
"Post-IPO ESOP"	means	the Company's post-IPO employee share option plan
"Post-IPO RSU Scheme"	means	the Company's post-IPO restricted share award scheme
"Preferred Share(s)"	means	preferred share(s) in the share capital of the Company prior to the Listing
"Pre-IPO Incentivization Plan"	means	the Company's pre-IPO employee equity plan
"Prospectus"	means	the prospectus of the Company, dated February 14, 2019, in relation to the Global Offering
"Reporting Period"	means	the six-month period from January 1, 2025 to June 30, 2025

Definitions

"RET"	means	rearranged during transfection
"RMB" or "Renminbi"	means	Renminbi Yuan, the lawful currency of China
"RSU(s)"	means	restricted share unit(s)
"Securities Transactions Code"	means	the code of conduct of the Company regarding Directors' securities transactions, namely the Policy on Management of Securities Transactions by Directors
"SFO"	means	the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), as amended, supplemented or otherwise modified from time to time
"Share(s)"	means	ordinary share(s) of US$0.0001 each in the issued share capital of our Company
"Share Incentivization Schemes"	means	the Pre-IPO Incentivization Plan, Post-IPO ESOP and Post-IPO RSU Scheme
"Shareholder(s)"	means	holder(s) of Shares
"SM"	means	systemic mastocytosis, a form of mastocytosis, in which mast cells accumulate in internal tissues and organs such as the liver, spleen, bone marrow, and small intestines
"Stock Exchange"	means	The Stock Exchange of Hong Kong Limited
"Strategy Committee"	means	the strategy committee of the Board
"treasury Share(s)"	means	has the meaning ascribed to it under the Listing Rules
"U.S."	means	United States of America
"U.S. FDA" or "FDA"	means	U.S. Food and Drug Administration
"USD" or "US$" or "US dollars"	means	United States Dollars, the lawful currency of the United States of America
"%"	means	per cent.

In this report, unless otherwise indicated, the terms "associate", "associated corporation", "connected person", "controlling shareholder", "subsidiary" and "substantial shareholder" shall have the meanings given to such terms in the Listing Rules.


基石药业
CSTONE
PHARMACEUTICALS